Annie12345的个人主页 - 老虎社区

Annie12345

Annie12345

暂无个人介绍

IP属地：未知

613关注

42粉丝

0主题

0勋章

2021-12-14

Yea

外媒头条：美联储可能上演历史罕见鹰派转变

2021-12-13

Ok

@Deonc:Sea Limited drops to end week

2021-12-13

O

@问就是加仓up:2021年复盘：大赚到接近清零，回本绝对是最浪漫的事

2021-12-01

Hopefully today turn green

Oversold Singapore Bourse Called Lower Again<blockquote>超卖的新加坡证券交易所再次下调</blockquote>

2021-11-27

Ok

@FundMall:Fund College: When should you take profit?

2021-11-27

O

抱歉，原内容已删除

2021-11-27

Haiz

抱歉，原内容已删除

2021-11-21

Lol

UBS Picks Former Morgan Stanley President Kelleher As chairman, Deutsche Bank Nominates Alexander Wynaendts As Next Chairman<blockquote>瑞银选择摩根士丹利前总裁凯莱赫为董事长，德意志银行提名亚历山大·怀南茨为下一任董事长</blockquote>

2021-11-14

like

Apple: The Bear Argument, And Why It's Wrong<blockquote>苹果：熊市论点及其错误的原因</blockquote>

2021-11-13

Like

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>

2021-11-12

Like

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573948076022422","uuid":"3573948076022422","gmtCreate":1610893425069,"gmtModify":1704447516716,"name":"Annie12345","pinyin":"annie12345","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":42,"headSize":613,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.28%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.31%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":604455354,"gmtCreate":1639441217413,"gmtModify":1639441217858,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Yea&nbsp;","listText":"Yea&nbsp;","text":"Yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604455354","repostId":"2191098415","repostType":2,"repost":{"id":"2191098415","kind":"news","pubTimestamp":1639431600,"share":"https://www.laohu8.com/m/news/2191098415?lang=zh_CN&edition=full","pubTime":"2021-12-14 05:40","market":"sh","language":"zh","title":"外媒头条：美联储可能上演历史罕见鹰派转变","url":"https://stock-news.laohu8.com/highlight/detail?id=2191098415","media":"市场资讯","summary":"　　纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。　　这一结果凸显出近期令美联储和大多数经济学家感到意外的通胀飙升的不可预测性。美联储可能在即将召开的政策会议上宣布加快减码债券收购的步伐。　　经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。","content":"<p><b>全球财经媒体昨夜今晨共同关注的头条新闻主要有：</b></p>\n<blockquote>\n <b>1、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高</b>\n</blockquote>\n<blockquote>\n <b>2、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变</b>\n</blockquote>\n<blockquote>\n <b>3、<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>CEO埃隆·马斯克当选时代杂志2021年度风云人物</b>\n</blockquote>\n<blockquote>\n <b>4、牛津大学：omicron毒株能削弱两针<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>或<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>疫苗的保护力</b>\n</blockquote>\n<blockquote>\n <b>5、七国集团财长承诺解决供应链问题并避免未来重演</b>\n</blockquote>\n<blockquote>\n <b>6、小摩预计美失业率明年将降至3%左右&nbsp;奥密克戎是就业市场主要风险</b>\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/ce56c82d6c11f45604012124909fbdc4\" tg-width=\"550\" tg-height=\"313\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高</b></p>\n<p>纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。</p>\n<p>调查还显示，三年通胀预期自6月以来首次下降，达到4%，主要是受到无大学学历受访者的预期推动。然而，无论是短期还是长期，通胀的不确定性水平都在上升，并且都达到了历史新高。</p>\n<p>这一结果凸显出近期令美联储和大多数经济学家感到意外的通胀飙升的不可预测性。美联储可能在即将召开的政策会议上宣布加快减码债券收购的步伐。</p>\n<p>调查还显示，消费者对经济的乐观程度下降。</p>\n<p>调查显示，美国未来一年失业率上升的平均概率提高了0.6个百分点。11月受访者对与一年前相比家庭当前财务状况的看法有所恶化，更多受访者称财务状况变差。</p>\n<p><img src=\"https://static.tigerbbs.com/ad8e2ae248c8736422a112e3a316d6b9\" tg-width=\"550\" tg-height=\"310\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>加速减码+预告加息 美联储可能上演历史罕见的鹰派转变</b></p>\n<p>经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。</p>\n<p>超过一半的受访者预计，美联储周三结束两天政策会议后发布的季度预测将显示，18位官员的中值预测是明年加息两次。</p>\n<p>这与他们9月份的预测相比有变化。当时，决策者在2022年或2023年首次加息的预测上平分秋色。</p>\n<p>“这将是点阵图历史上最大的鹰派转变，”Macropolicy Perspectives高级经济学家Laura Rosner-Warburton表示。美联储自2012年开始发布利率预测的点阵图。</p>\n<p><img src=\"https://n.sinaimg.cn/tech/transform/395/w512h683/20211213/2dd2-a526974a89f50d8229b23ab688835d45.png\" tg-width=\"512\" tg-height=\"683\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物</b></p>\n<p>据报道，特斯拉CEO埃隆·马斯克（Elon Musk）今日被美国《时代》杂志评为“2021年度风云人物”。</p>\n<p>《时代》杂志称，作为世界上最富有的人，他没有房子，最近一直在抛售财产。他将卫星送入轨道，并利用<a href=\"https://laohu8.com/S/000591\">太阳能</a>服务千家万户。他驾驶着一辆自己制造的汽车，不需要汽油，也几乎不需要司机。他的手指一挥，股市就会暴涨或暴跌。他的每一句话都被一大群粉丝挂在嘴边。当他把业务推向全球时，还梦想着移民火星。</p>\n<p><img src=\"https://static.tigerbbs.com/4133304c52fa226b469ba60f980192f1\" tg-width=\"550\" tg-height=\"310\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力</b></p>\n<p>研究人员发现，正如人们所担忧的一样，omicron变异株削弱了辉瑞和阿斯利康两剂新冠疫苗所能提供的保护力，增加了接种者感染风险。</p>\n<p>牛津大学研究人员周一在一份报告中表示，在对接种辉瑞或阿斯利康疫苗的人采集的血液样本中，经检测新毒株omicron令中和抗体大幅减少，尤其是和德尔塔毒株相比，降幅很明显。</p>\n<p>阿斯利康疫苗的创造者之一Teresa Lambe表示，在接下来的几周，omicron的影响应该会得到更好的记录，以明确是否需要接种新疫苗。</p>\n<p>“我们希望当前的疫苗能够预防严重疾病和住院治疗”，Lambe表示。 “我们和其他疫苗生产商的立场是，如果需要一种针对新毒株的疫苗，我们可以快速推进。”</p>\n<p><img src=\"https://static.tigerbbs.com/7eb99a948e8b987f3e2c4401c8f7e901\" tg-width=\"550\" tg-height=\"309\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>七国集团财长承诺解决供应链问题并避免未来重演</b></p>\n<p>七国集团财长承诺加强合作，以解决造成商品短缺和通胀飙升的全球供应链问题。</p>\n<p>由于运输问题导致供应中断，零部件制成品短缺以及疫情造成能源价格上涨，全球消费者价格都在飙升。美国通胀率已触及1982年以来的最高水平，欧元区通胀率达到了创纪录的4.9%。</p>\n<p>在七国集团财长和央行行长会议的最后公报中，轮值主席国英国的财政大臣Rishi Sunak称，该组织将着眼于预测并避免未来的供应紧张。</p>\n<p>英国财政部表示，七国集团财长和央行行长们“就如何提高供应链韧性以及如何更准确地预测未来可能发生的干扰交换了看法”。</p>\n<p><img src=\"https://static.tigerbbs.com/5d92536ec41518383402813fee58b8bc\" tg-width=\"550\" tg-height=\"407\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>小摩预计美失业率明年将降至3%左右&nbsp;奥密克戎是就业市场主要风险</b></p>\n<p><a href=\"https://laohu8.com/S/JPM\">摩根大通</a>首席美国经济学家Michael Feroli认为，2022年美国失业率将下降。</p>\n<p>“我认为到2022年底可以看到失业率在3%左右，”Feroli称。“过去五个月的失业率下降幅度令人深刻印象。我们预计下降速度会放缓，但很快就会降至4%以下。”</p>\n<p>在Feroli看来，随着雇主寻找人才以推动企业从疫情中复苏，就业市场可能会以良好的势头进入2022年。</p>\n<p>Feroli还预计，明年美国GDP将增长3%。他认为，美联储将在9月开始加息以抵消通胀，而通胀在一定程度上是由于劳动力市场状况吃紧。</p>\n<p>此外，就业市场的一个主要风险仍然是奥密克戎变体及其是否会减缓企业的招聘计划。</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>外媒头条：美联储可能上演历史罕见鹰派转变</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n外媒头条：美联储可能上演历史罕见鹰派转变\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 05:40 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2021-12-14/doc-ikyakumx3975846.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高\n\n\n2、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变\n\n\n3、特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物\n\n\n4、牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力\n\n\n5、七国集团财长承诺解决供应链问题并避免未来重演\n\n\n6、小摩预计美失业率明年将...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-12-14/doc-ikyakumx3975846.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/02a85629f2a809e4eabd8677140a5f70","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","DJX":"1/100道琼斯","DDM":"2倍做多道指ETF-ProShares","OEX":"标普100","DXD":"两倍做空道琼30指数ETF-ProShares",".IXIC":"NASDAQ Composite","DOG":"道指ETF-ProShares做空","SQQQ":"纳指三倍做空ETF","UDOW":"三倍做多道指30ETF-ProShares",".SPX":"S&P 500 Index","UPRO":"三倍做多标普500ETF-ProShares","IVV":"标普500ETF-iShares","PSQ":"做空纳斯达克100指数ETF-ProShares","QQQ":"纳指100ETF","SH":"做空标普500-Proshares","SPXU":"三倍做空标普500ETF-ProShares",".DJI":"道琼斯","BK4534":"瑞士信贷持仓","SSO":"2倍做多标普500ETF-ProShares","TQQQ":"纳指三倍做多ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SDOW":"三倍做空道指30ETF-ProShares","SPY":"标普500ETF","BK4504":"桥水持仓","SDS":"两倍做空标普500 ETF-ProShares","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","QID":"两倍做空纳斯达克指数ETF-ProShares"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-12-14/doc-ikyakumx3975846.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2191098415","content_text":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高\n\n\n2、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变\n\n\n3、特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物\n\n\n4、牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力\n\n\n5、七国集团财长承诺解决供应链问题并避免未来重演\n\n\n6、小摩预计美失业率明年将降至3%左右 奥密克戎是就业市场主要风险\n\n\n纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高\n纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。\n调查还显示，三年通胀预期自6月以来首次下降，达到4%，主要是受到无大学学历受访者的预期推动。然而，无论是短期还是长期，通胀的不确定性水平都在上升，并且都达到了历史新高。\n这一结果凸显出近期令美联储和大多数经济学家感到意外的通胀飙升的不可预测性。美联储可能在即将召开的政策会议上宣布加快减码债券收购的步伐。\n调查还显示，消费者对经济的乐观程度下降。\n调查显示，美国未来一年失业率上升的平均概率提高了0.6个百分点。11月受访者对与一年前相比家庭当前财务状况的看法有所恶化，更多受访者称财务状况变差。\n\n加速减码+预告加息 美联储可能上演历史罕见的鹰派转变\n经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。\n超过一半的受访者预计，美联储周三结束两天政策会议后发布的季度预测将显示，18位官员的中值预测是明年加息两次。\n这与他们9月份的预测相比有变化。当时，决策者在2022年或2023年首次加息的预测上平分秋色。\n“这将是点阵图历史上最大的鹰派转变，”Macropolicy Perspectives高级经济学家Laura Rosner-Warburton表示。美联储自2012年开始发布利率预测的点阵图。\n\n特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物\n据报道，特斯拉CEO埃隆·马斯克（Elon Musk）今日被美国《时代》杂志评为“2021年度风云人物”。\n《时代》杂志称，作为世界上最富有的人，他没有房子，最近一直在抛售财产。他将卫星送入轨道，并利用太阳能服务千家万户。他驾驶着一辆自己制造的汽车，不需要汽油，也几乎不需要司机。他的手指一挥，股市就会暴涨或暴跌。他的每一句话都被一大群粉丝挂在嘴边。当他把业务推向全球时，还梦想着移民火星。\n\n牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力\n研究人员发现，正如人们所担忧的一样，omicron变异株削弱了辉瑞和阿斯利康两剂新冠疫苗所能提供的保护力，增加了接种者感染风险。\n牛津大学研究人员周一在一份报告中表示，在对接种辉瑞或阿斯利康疫苗的人采集的血液样本中，经检测新毒株omicron令中和抗体大幅减少，尤其是和德尔塔毒株相比，降幅很明显。\n阿斯利康疫苗的创造者之一Teresa Lambe表示，在接下来的几周，omicron的影响应该会得到更好的记录，以明确是否需要接种新疫苗。\n“我们希望当前的疫苗能够预防严重疾病和住院治疗”，Lambe表示。 “我们和其他疫苗生产商的立场是，如果需要一种针对新毒株的疫苗，我们可以快速推进。”\n\n七国集团财长承诺解决供应链问题并避免未来重演\n七国集团财长承诺加强合作，以解决造成商品短缺和通胀飙升的全球供应链问题。\n由于运输问题导致供应中断，零部件制成品短缺以及疫情造成能源价格上涨，全球消费者价格都在飙升。美国通胀率已触及1982年以来的最高水平，欧元区通胀率达到了创纪录的4.9%。\n在七国集团财长和央行行长会议的最后公报中，轮值主席国英国的财政大臣Rishi Sunak称，该组织将着眼于预测并避免未来的供应紧张。\n英国财政部表示，七国集团财长和央行行长们“就如何提高供应链韧性以及如何更准确地预测未来可能发生的干扰交换了看法”。\n\n小摩预计美失业率明年将降至3%左右 奥密克戎是就业市场主要风险\n摩根大通首席美国经济学家Michael Feroli认为，2022年美国失业率将下降。\n“我认为到2022年底可以看到失业率在3%左右，”Feroli称。“过去五个月的失业率下降幅度令人深刻印象。我们预计下降速度会放缓，但很快就会降至4%以下。”\n在Feroli看来，随着雇主寻找人才以推动企业从疫情中复苏，就业市场可能会以良好的势头进入2022年。\nFeroli还预计，明年美国GDP将增长3%。他认为，美联储将在9月开始加息以抵消通胀，而通胀在一定程度上是由于劳动力市场状况吃紧。\n此外，就业市场的一个主要风险仍然是奥密克戎变体及其是否会减缓企业的招聘计划。","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"DOG":0.9,"ESmain":0.9,"DDM":0.9,"SQQQ":0.9,"QID":0.9,"MNQmain":0.9,".IXIC":0.9,"OEX":0.9,"SDS":0.9,".SPX":0.9,"TQQQ":0.9,".DJI":0.9,"QLD":0.9,"PSQ":0.9,"SPY":0.9,"NQmain":0.9,"OEF":0.9,"QQQ":0.9,"UPRO":0.9,"UDOW":0.9,"SDOW":0.9,"SSO":0.9,"DJX":0.9,"SPXU":0.9,"IVV":0.9,"SH":0.9,"DXD":0.9}},"isVote":1,"tweetType":1,"viewCount":2228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604800763,"gmtCreate":1639364649863,"gmtModify":1639364924275,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604800763","repostId":"605462650","repostType":1,"repost":{"id":605462650,"gmtCreate":1639222201797,"gmtModify":1639233253732,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569316529855154","authorIdStr":"3569316529855154"},"themes":[],"title":"Sea Limited drops to end week","htmlText":"Sea Limited drops to end week as Hedgeye calls it a top short idea Back view of young gamer playing video games on computerSea Limited (NYSE:SE) ended the week on a low note, dropping 6.6% today after being named as a best idea short at Hedgeye.Shares had pulled back some 30% from their all-time highs already, analyst Felix Wang notes, but says the valuation is still \"lofty\" - and has room for another 35% downside.The company is facing more competitive pressure, he says, and some of the routes forward aren't as solid as expected. Sea is looking to Brazil to support international growth, but Wang says the gaming opportunity in Brazil is \"hyped\" and e-commerce there is shaky as well.As for its flagship game Garena Free Fire, it's a \"one-hit wonder whose performance has peaked,\" with engageme","listText":"Sea Limited drops to end week as Hedgeye calls it a top short idea Back view of young gamer playing video games on computerSea Limited (NYSE:SE) ended the week on a low note, dropping 6.6% today after being named as a best idea short at Hedgeye.Shares had pulled back some 30% from their all-time highs already, analyst Felix Wang notes, but says the valuation is still \"lofty\" - and has room for another 35% downside.The company is facing more competitive pressure, he says, and some of the routes forward aren't as solid as expected. Sea is looking to Brazil to support international growth, but Wang says the gaming opportunity in Brazil is \"hyped\" and e-commerce there is shaky as well.As for its flagship game Garena Free Fire, it's a \"one-hit wonder whose performance has peaked,\" with engageme","text":"Sea Limited drops to end week as Hedgeye calls it a top short idea Back view of young gamer playing video games on computerSea Limited (NYSE:SE) ended the week on a low note, dropping 6.6% today after being named as a best idea short at Hedgeye.Shares had pulled back some 30% from their all-time highs already, analyst Felix Wang notes, but says the valuation is still \"lofty\" - and has room for another 35% downside.The company is facing more competitive pressure, he says, and some of the routes forward aren't as solid as expected. Sea is looking to Brazil to support international growth, but Wang says the gaming opportunity in Brazil is \"hyped\" and e-commerce there is shaky as well.As for its flagship game Garena Free Fire, it's a \"one-hit wonder whose performance has peaked,\" with engageme","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605462650","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604800494,"gmtCreate":1639364635421,"gmtModify":1639364923690,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604800494","repostId":"605477626","repostType":1,"repost":{"id":605477626,"gmtCreate":1639236121452,"gmtModify":1747987191807,"author":{"id":"3548388348794551","authorId":"3548388348794551","name":"问就是加仓up","avatar":"https://static.tigerbbs.com/4e98ddf789d46c5627f944fc581c0fe9","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548388348794551","authorIdStr":"3548388348794551"},"themes":[],"title":"2021年复盘：大赚到接近清零，回本绝对是最浪漫的事","htmlText":"又到了年底复盘的时候，今年炒股体验真的极度复杂，年初觉得自己是股神， 年中觉得自己是韭菜，年底两个月又觉得自己能行了。这一年心路历程不是一篇帖子能够描述的，但还是希望通过年度复盘给大家还原一些比较有意义的观点。 这是去年的复盘链接&nbsp;&nbsp;<a href=\"https://laohu8.com/TW/331834662\" target=\"_blank\">2020总结：美股10倍，港股2倍，A股：赚钱是甚么</a> 今年的复盘主要分5个部分，收益复盘，操作复盘，一些感悟，交易手法，未来展望。文章有点长，可以直接跳转看自己感兴趣的部分。 1，收益：勉强保本 今年账户保本小赚，年中的时候一度大亏，在10月份开始飞速回本了，之后一路操作很多，但是也没啥大的收益。至于说收益图基本上也没法看，因为今年出入金频率太高，曲线都是-99%，因为中途出现过账户暴跌。但是由于控制了账户资金，没有受伤很严重。 这个图是12月10日截图，截止到今天一共交易了470w美金，交易频率比较高。累计交易了205只，其中盈利的只有43只，基本上就是赚钱的拿得住，赔钱的跑得快，当然也因此卖飞了不少股票。截止到今天一共挣了1600刀，收益率多少，我也不知道，根本算不出来。 另外今年开了N多的账户打新（几十个），这也是资金进出频繁的一个原因，不过这些账户都是亏钱出局，4月份之后基本上不打新了，打新是今年的一个重要亏损点。如果把所有账户加起来，今年基本上没赚钱，因为还有一个大账户也小有盈利，差不多可以把各种打野的亏损平衡掉。 2，操作复盘 每个月都有一些神之操作，每个月都有不一样的槽点。文中的时间节点可能记得不是那么清晰，相关操作之前发帖子也有提过，主要说一些印象比较深刻的。 1月份 中概股暴涨完整的吃到了，而且这也是账户高频交易的开始，当时买老虎股票，从6美金涨到了38美金（环球账户被清空了，没法晒）","listText":"又到了年底复盘的时候，今年炒股体验真的极度复杂，年初觉得自己是股神， 年中觉得自己是韭菜，年底两个月又觉得自己能行了。这一年心路历程不是一篇帖子能够描述的，但还是希望通过年度复盘给大家还原一些比较有意义的观点。 这是去年的复盘链接&nbsp;&nbsp;<a href=\"https://laohu8.com/TW/331834662\" target=\"_blank\">2020总结：美股10倍，港股2倍，A股：赚钱是甚么</a> 今年的复盘主要分5个部分，收益复盘，操作复盘，一些感悟，交易手法，未来展望。文章有点长，可以直接跳转看自己感兴趣的部分。 1，收益：勉强保本 今年账户保本小赚，年中的时候一度大亏，在10月份开始飞速回本了，之后一路操作很多，但是也没啥大的收益。至于说收益图基本上也没法看，因为今年出入金频率太高，曲线都是-99%，因为中途出现过账户暴跌。但是由于控制了账户资金，没有受伤很严重。 这个图是12月10日截图，截止到今天一共交易了470w美金，交易频率比较高。累计交易了205只，其中盈利的只有43只，基本上就是赚钱的拿得住，赔钱的跑得快，当然也因此卖飞了不少股票。截止到今天一共挣了1600刀，收益率多少，我也不知道，根本算不出来。 另外今年开了N多的账户打新（几十个），这也是资金进出频繁的一个原因，不过这些账户都是亏钱出局，4月份之后基本上不打新了，打新是今年的一个重要亏损点。如果把所有账户加起来，今年基本上没赚钱，因为还有一个大账户也小有盈利，差不多可以把各种打野的亏损平衡掉。 2，操作复盘 每个月都有一些神之操作，每个月都有不一样的槽点。文中的时间节点可能记得不是那么清晰，相关操作之前发帖子也有提过，主要说一些印象比较深刻的。 1月份 中概股暴涨完整的吃到了，而且这也是账户高频交易的开始，当时买老虎股票，从6美金涨到了38美金（环球账户被清空了，没法晒）","text":"又到了年底复盘的时候，今年炒股体验真的极度复杂，年初觉得自己是股神， 年中觉得自己是韭菜，年底两个月又觉得自己能行了。这一年心路历程不是一篇帖子能够描述的，但还是希望通过年度复盘给大家还原一些比较有意义的观点。 这是去年的复盘链接 2020总结：美股10倍，港股2倍，A股：赚钱是甚么 今年的复盘主要分5个部分，收益复盘，操作复盘，一些感悟，交易手法，未来展望。文章有点长，可以直接跳转看自己感兴趣的部分。 1，收益：勉强保本 今年账户保本小赚，年中的时候一度大亏，在10月份开始飞速回本了，之后一路操作很多，但是也没啥大的收益。至于说收益图基本上也没法看，因为今年出入金频率太高，曲线都是-99%，因为中途出现过账户暴跌。但是由于控制了账户资金，没有受伤很严重。 这个图是12月10日截图，截止到今天一共交易了470w美金，交易频率比较高。累计交易了205只，其中盈利的只有43只，基本上就是赚钱的拿得住，赔钱的跑得快，当然也因此卖飞了不少股票。截止到今天一共挣了1600刀，收益率多少，我也不知道，根本算不出来。 另外今年开了N多的账户打新（几十个），这也是资金进出频繁的一个原因，不过这些账户都是亏钱出局，4月份之后基本上不打新了，打新是今年的一个重要亏损点。如果把所有账户加起来，今年基本上没赚钱，因为还有一个大账户也小有盈利，差不多可以把各种打野的亏损平衡掉。 2，操作复盘 每个月都有一些神之操作，每个月都有不一样的槽点。文中的时间节点可能记得不是那么清晰，相关操作之前发帖子也有提过，主要说一些印象比较深刻的。 1月份 中概股暴涨完整的吃到了，而且这也是账户高频交易的开始，当时买老虎股票，从6美金涨到了38美金（环球账户被清空了，没法晒）","images":[{"img":"https://static.tigerbbs.com/fad4be5c0b8c595847d68aaeb0d403c7","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/b997c7eb8dab40ed1a413c3502e16b53","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/ccf5b3b2ff1b8703b1e8a4f1dfac346c","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605477626","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":1,"comments":[],"imageCount":16,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609468359,"gmtCreate":1638318245027,"gmtModify":1638318245250,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Hopefully today turn green&nbsp;","listText":"Hopefully today turn green&nbsp;","text":"Hopefully today turn green","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609468359","repostId":"1129769141","repostType":4,"repost":{"id":"1129769141","kind":"news","pubTimestamp":1638317199,"share":"https://www.laohu8.com/m/news/1129769141?lang=zh_CN&edition=full","pubTime":"2021-12-01 08:06","market":"us","language":"en","title":"Oversold Singapore Bourse Called Lower Again<blockquote>超卖的新加坡证券交易所再次下调</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129769141","media":"RTTNews","summary":"The Singapore stock market has finished lower in six straight trading days, sinking almost 200 point","content":"<p>The Singapore stock market has finished lower in six straight trading days, sinking almost 200 points or 6.4 percent along the way. The Straits Times Index now sits just above the 3,040-point plateau and it's got another weak lead for Wednesday's trade.</p><p><blockquote>新加坡股市连续六个交易日收低，跌幅近200点，跌幅6.4%。海峡时报指数目前略高于3,040点的高位，周三的交易再次小幅领先。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;suggests consolidation on continued COVID-19 worries and concerns over the outlook for interest rates. The European and U.S. markets were down and the Asian markets figure to open in similar fashion.</p><p><blockquote>对亚洲市场的全球预测表明，对新冠肺炎的持续担忧和对利率前景的担忧将会巩固。欧洲和美国市场下跌，亚洲市场预计也将以类似的方式开盘。</blockquote></p><p> The STI finished sharply lower on Tuesday with damage across the board, especially from the financials and industrials.</p><p><blockquote>海指周二大幅收低，全线受损，尤其是金融和工业股。</blockquote></p><p> For the day, the index plunged 79.29 points or 2.54 percent to finish at the daily low of 3,041.29 after peaking at 3,129.54. Volume was 3.22 billion shares worth 3.89 billion Singapore dollars. There were 338 decliners and 172 gainers.</p><p><blockquote>当天，该指数暴跌79.29点或2.54%，收于3,041.29点的日低，此前曾触及3,129.54点。成交量为32.2亿股，价值38.9亿新元。下跌股338家，上涨股172家。</blockquote></p><p> Among the actives, Ascendas REIT slumped 2.34 percent, while CapitaLand Integrated Commercial Trust and Jardine Cycle both fell 1.40 percent, City Developments added 0.29 percent, Comfort DelGro plummeted 4.20 percent, Dairy Farm International and Thai Beverage both weakened 2.19 percent, DBS Group declined 2.99 percent, Genting Singapore skidded 2.53 percent, Keppel Corp sank 2.11 percent, Mapletree Commercial Trust stumbled 2.39 percent, Mapletree Logistics Trust lost 1.87 percent, Oversea-Chinese Banking Corporation surrendered 3.17 percent, SATS retreated 2.56 percent, SembCorp Industries plunged 4.08 percent, Singapore Airlines slid 0.81 percent, Singapore Exchange tumbled 3.25 percent, Singapore Press Holdings eased 0.43 percent, Singapore Technologies Engineering was down 0.78 percent, SingTel dropped 2.07 percent, United Overseas Bank tanked 4.00 percent, Wilmar International shed 1.91 percent and Yangzijiang Shipbuilding was unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌2.34%，凯德综合商业信托和怡和周期均下跌1.40%，城市发展上涨0.29%，舒适德尔高暴跌4.20%，乳业国际和泰国饮料均下跌2.19%，星展集团下跌2.99%，云顶新加坡下跌2.53%，吉宝企业下跌2.11%，丰树商业信托下跌2.39%，丰树物流信托下跌1.87%，华侨银行下跌3.17%，胜科工业下跌4.08%，新加坡航空下跌0.81%，新加坡科技工程下跌0.78%，新加坡电信下跌2.07%，丰益国际下跌1.91%，扬子江造船持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened lower on Tuesday and remained largely under water throughout the trading day.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周二开盘走低，整个交易日基本保持在水下。</blockquote></p><p></p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oversold Singapore Bourse Called Lower Again<blockquote>超卖的新加坡证券交易所再次下调</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOversold Singapore Bourse Called Lower Again<blockquote>超卖的新加坡证券交易所再次下调</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">RTTNews</strong><span class=\"h-time small\">2021-12-01 08:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Singapore stock market has finished lower in six straight trading days, sinking almost 200 points or 6.4 percent along the way. The Straits Times Index now sits just above the 3,040-point plateau and it's got another weak lead for Wednesday's trade.</p><p><blockquote>新加坡股市连续六个交易日收低，跌幅近200点，跌幅6.4%。海峡时报指数目前略高于3,040点的高位，周三的交易再次小幅领先。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;suggests consolidation on continued COVID-19 worries and concerns over the outlook for interest rates. The European and U.S. markets were down and the Asian markets figure to open in similar fashion.</p><p><blockquote>对亚洲市场的全球预测表明，对新冠肺炎的持续担忧和对利率前景的担忧将会巩固。欧洲和美国市场下跌，亚洲市场预计也将以类似的方式开盘。</blockquote></p><p> The STI finished sharply lower on Tuesday with damage across the board, especially from the financials and industrials.</p><p><blockquote>海指周二大幅收低，全线受损，尤其是金融和工业股。</blockquote></p><p> For the day, the index plunged 79.29 points or 2.54 percent to finish at the daily low of 3,041.29 after peaking at 3,129.54. Volume was 3.22 billion shares worth 3.89 billion Singapore dollars. There were 338 decliners and 172 gainers.</p><p><blockquote>当天，该指数暴跌79.29点或2.54%，收于3,041.29点的日低，此前曾触及3,129.54点。成交量为32.2亿股，价值38.9亿新元。下跌股338家，上涨股172家。</blockquote></p><p> Among the actives, Ascendas REIT slumped 2.34 percent, while CapitaLand Integrated Commercial Trust and Jardine Cycle both fell 1.40 percent, City Developments added 0.29 percent, Comfort DelGro plummeted 4.20 percent, Dairy Farm International and Thai Beverage both weakened 2.19 percent, DBS Group declined 2.99 percent, Genting Singapore skidded 2.53 percent, Keppel Corp sank 2.11 percent, Mapletree Commercial Trust stumbled 2.39 percent, Mapletree Logistics Trust lost 1.87 percent, Oversea-Chinese Banking Corporation surrendered 3.17 percent, SATS retreated 2.56 percent, SembCorp Industries plunged 4.08 percent, Singapore Airlines slid 0.81 percent, Singapore Exchange tumbled 3.25 percent, Singapore Press Holdings eased 0.43 percent, Singapore Technologies Engineering was down 0.78 percent, SingTel dropped 2.07 percent, United Overseas Bank tanked 4.00 percent, Wilmar International shed 1.91 percent and Yangzijiang Shipbuilding was unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌2.34%，凯德综合商业信托和怡和周期均下跌1.40%，城市发展上涨0.29%，舒适德尔高暴跌4.20%，乳业国际和泰国饮料均下跌2.19%，星展集团下跌2.99%，云顶新加坡下跌2.53%，吉宝企业下跌2.11%，丰树商业信托下跌2.39%，丰树物流信托下跌1.87%，华侨银行下跌3.17%，胜科工业下跌4.08%，新加坡航空下跌0.81%，新加坡科技工程下跌0.78%，新加坡电信下跌2.07%，丰益国际下跌1.91%，扬子江造船持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened lower on Tuesday and remained largely under water throughout the trading day.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周二开盘走低，整个交易日基本保持在水下。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.rttnews.com/3245823/oversold-singapore-bourse-called-lower-again.aspx?type=acom\">RTTNews</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"C6L.SI":"新加坡航空公司","BVA.SI":"顶级手套有限公司","STI.SI":"富时新加坡海峡指数","O39.SI":"华侨银行","D05.SI":"星展集团控股"},"source_url":"https://www.rttnews.com/3245823/oversold-singapore-bourse-called-lower-again.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129769141","content_text":"The Singapore stock market has finished lower in six straight trading days, sinking almost 200 points or 6.4 percent along the way. The Straits Times Index now sits just above the 3,040-point plateau and it's got another weak lead for Wednesday's trade.\nThe global forecast for the Asian markets suggests consolidation on continued COVID-19 worries and concerns over the outlook for interest rates. The European and U.S. markets were down and the Asian markets figure to open in similar fashion.\nThe STI finished sharply lower on Tuesday with damage across the board, especially from the financials and industrials.\nFor the day, the index plunged 79.29 points or 2.54 percent to finish at the daily low of 3,041.29 after peaking at 3,129.54. Volume was 3.22 billion shares worth 3.89 billion Singapore dollars. There were 338 decliners and 172 gainers.\nAmong the actives, Ascendas REIT slumped 2.34 percent, while CapitaLand Integrated Commercial Trust and Jardine Cycle both fell 1.40 percent, City Developments added 0.29 percent, Comfort DelGro plummeted 4.20 percent, Dairy Farm International and Thai Beverage both weakened 2.19 percent, DBS Group declined 2.99 percent, Genting Singapore skidded 2.53 percent, Keppel Corp sank 2.11 percent, Mapletree Commercial Trust stumbled 2.39 percent, Mapletree Logistics Trust lost 1.87 percent, Oversea-Chinese Banking Corporation surrendered 3.17 percent, SATS retreated 2.56 percent, SembCorp Industries plunged 4.08 percent, Singapore Airlines slid 0.81 percent, Singapore Exchange tumbled 3.25 percent, Singapore Press Holdings eased 0.43 percent, Singapore Technologies Engineering was down 0.78 percent, SingTel dropped 2.07 percent, United Overseas Bank tanked 4.00 percent, Wilmar International shed 1.91 percent and Yangzijiang Shipbuilding was unchanged.\nThe lead from Wall Street is broadly negative as the major averages opened lower on Tuesday and remained largely under water throughout the trading day.","news_type":1,"symbols_score_info":{"D05.SI":0.9,"STI.SI":0.9,"C6L.SI":0.9,"BVA.SI":0.9,"O39.SI":0.9}},"isVote":1,"tweetType":1,"viewCount":2426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600079187,"gmtCreate":1638023420408,"gmtModify":1638023420654,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600079187","repostId":"875206593","repostType":1,"repost":{"id":875206593,"gmtCreate":1637653011508,"gmtModify":1637923972899,"author":{"id":"3585780691540522","authorId":"3585780691540522","name":"FundMall","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585780691540522","authorIdStr":"3585780691540522"},"themes":[],"title":"Fund College: When should you take profit?","htmlText":"One pertinent question investors commonly ask themselves is: ‘when should I take profits?’. This is no doubt a tough question to answer since we as investors are always seeking higher returns from our investments. In today’s article, we will break down our thoughts on this topic for our platform’s investors. To begin with, there is nothing wrong with chasing more returns despite having your investments in the green. However, we think that it is a good practice to review your portfolio at the end of the year or even the start of the year, even if you have a time horizon of ten years or more, given that sometimes a certain investment may become a huge part in your portfolio, especially if it has rallied aggressively. Take for example you have invested in the technology sector during the Covi","listText":"One pertinent question investors commonly ask themselves is: ‘when should I take profits?’. This is no doubt a tough question to answer since we as investors are always seeking higher returns from our investments. In today’s article, we will break down our thoughts on this topic for our platform’s investors. To begin with, there is nothing wrong with chasing more returns despite having your investments in the green. However, we think that it is a good practice to review your portfolio at the end of the year or even the start of the year, even if you have a time horizon of ten years or more, given that sometimes a certain investment may become a huge part in your portfolio, especially if it has rallied aggressively. Take for example you have invested in the technology sector during the Covi","text":"One pertinent question investors commonly ask themselves is: ‘when should I take profits?’. This is no doubt a tough question to answer since we as investors are always seeking higher returns from our investments. In today’s article, we will break down our thoughts on this topic for our platform’s investors. To begin with, there is nothing wrong with chasing more returns despite having your investments in the green. However, we think that it is a good practice to review your portfolio at the end of the year or even the start of the year, even if you have a time horizon of ten years or more, given that sometimes a certain investment may become a huge part in your portfolio, especially if it has rallied aggressively. Take for example you have invested in the technology sector during the Covi","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875206593","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600070485,"gmtCreate":1638023358779,"gmtModify":1638023358976,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600070485","repostId":"2186344334","repostType":4,"isVote":1,"tweetType":1,"viewCount":2696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600070576,"gmtCreate":1638023352649,"gmtModify":1638023352846,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Haiz","listText":"Haiz","text":"Haiz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600070576","repostId":"2186344334","repostType":4,"isVote":1,"tweetType":1,"viewCount":2552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872622320,"gmtCreate":1637509764766,"gmtModify":1637509764996,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872622320","repostId":"1136453612","repostType":4,"repost":{"id":"1136453612","kind":"news","pubTimestamp":1637458211,"share":"https://www.laohu8.com/m/news/1136453612?lang=zh_CN&edition=full","pubTime":"2021-11-21 09:30","market":"us","language":"en","title":"UBS Picks Former Morgan Stanley President Kelleher As chairman, Deutsche Bank Nominates Alexander Wynaendts As Next Chairman<blockquote>瑞银选择摩根士丹利前总裁凯莱赫为董事长，德意志银行提名亚历山大·怀南茨为下一任董事长</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453612","media":"Benzinga ","summary":"UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman.\nA day before,","content":"<p><div> UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman. A day before,Deutsche Bank announced that it would nominate Dutch businessman Alexander Wynaendts as the next ...</p><p><blockquote><div>瑞银集团任命摩根士丹利前总裁科尔姆·凯莱赫为新任董事长。一天前，德意志银行宣布提名荷兰商人亚历山大·怀南茨为下一任...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Picks Former Morgan Stanley President Kelleher As chairman, Deutsche Bank Nominates Alexander Wynaendts As Next Chairman<blockquote>瑞银选择摩根士丹利前总裁凯莱赫为董事长，德意志银行提名亚历山大·怀南茨为下一任董事长</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Picks Former Morgan Stanley President Kelleher As chairman, Deutsche Bank Nominates Alexander Wynaendts As Next Chairman<blockquote>瑞银选择摩根士丹利前总裁凯莱赫为董事长，德意志银行提名亚历山大·怀南茨为下一任董事长</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga </strong><span class=\"h-time small\">2021-11-21 09:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman. A day before,Deutsche Bank announced that it would nominate Dutch businessman Alexander Wynaendts as the next ...</p><p><blockquote><div>瑞银集团任命摩根士丹利前总裁科尔姆·凯莱赫为新任董事长。一天前，德意志银行宣布提名荷兰商人亚历山大·怀南茨为下一任...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">Benzinga </a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBS":"瑞银"},"source_url":"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453612","content_text":"UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman.\nA day before,Deutsche Bank announced that it would nominate Dutch businessman Alexander Wynaendts as the next chairman of its supervisory board, following a turbulent decade for Germany’s largest lender.\nKelleher will succeed Axel Weber as UBS’s chairman next year. He takes the leadership role having spent three decades at Morgan Stanley, where he served as chief financial officer before rising to the position of president.\nAccording to Reuters, UBS’s board had included former UniCredit Chief Executive Jean-Pierre Mustier in a shortlist of possible candidates.\nIn October, UBS posted its highest quarterly profit over the past 11 years, with a 23% rise in fee income.\nSimilarly, Wynaendts will replace Paul Achleitner at Deutsche Bank. The bank's shares have fallen more than 50% since Achleitner became chairman, primarily due to massive regulatory fines and repeated capital raisings.\nWynaendts ran Dutch insurer Aegon NV for 12 years before leaving in 2020, and previously worked at ABN Amro’s investment banking and private banking units before joining Aegon in 1997.","news_type":1,"symbols_score_info":{"UBS":0.9}},"isVote":1,"tweetType":1,"viewCount":2722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873952288,"gmtCreate":1636849821806,"gmtModify":1636849821984,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873952288","repostId":"1129004768","repostType":4,"repost":{"id":"1129004768","kind":"news","pubTimestamp":1636764434,"share":"https://www.laohu8.com/m/news/1129004768?lang=zh_CN&edition=full","pubTime":"2021-11-13 08:47","market":"us","language":"en","title":"Apple: The Bear Argument, And Why It's Wrong<blockquote>苹果：熊市论点及其错误的原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129004768","media":"Seeking Alpha","summary":"Apple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.I list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.Maybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.This may also help to explain, in part, why Apple's revenues in Greater China shot through the","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.</li>  <li>I list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.</li>  <li>Maybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4bc955cc5d27328c3b89b327b9368d27\" tg-width=\"1536\" tg-height=\"1020\" width=\"100%\" height=\"auto\"><span>kmwphotography/iStock via Getty Images</span></p><p><blockquote><ul><li>苹果未能长期保持在每股150美元以上，空头开始关注近期价格的疲软。</li><li>我列出了几个最流行的看跌论点，并解释了为什么我认为它们要么是短视的，要么很可能是不正确的。</li><li>也许苹果公司并不是同样值得买入的股票，但我仍然认为这是一只今天值得在未来几年持有的股票。</li></ul><p class=\"t-img-caption\"><span>kmwphotography/iStock来自Getty Images</span></p></blockquote></p><p> With Apple (AAPL) once again failing to make fresh all-time highs, now down around 6% from the peak and dipping closer towards key moving-average support, bears have started to pay attention. Still, I think that the case for selling (or shorting) this stock does not hold much water in the long term, and I believe that bears will ultimately tire of swimming against the current.</p><p><blockquote>随着苹果(AAPL)再次未能创下历史新高，目前较峰值下跌约6%，并接近关键移动平均线支撑位，空头开始关注。尽管如此，我认为从长远来看，出售（或做空）这只股票的理由并不成立，而且我相信空头最终会厌倦逆流而上。</blockquote></p><p> Below, I list the most common few reasons why one might want to dump or stay away from Apple shares – and why I think that the bearish case is either short-sighted or most likely incorrect.</p><p><blockquote>下面，我列出了人们可能想要抛售或远离苹果股票的几个最常见的原因，以及为什么我认为看跌情况要么是短视的，要么很可能是不正确的。</blockquote></p><p> <b>Key risk #1: drop-off in demand</b></p><p><blockquote><b>关键风险#1：需求下降</b></blockquote></p><p> Not many analysts and portfolio managers have been vocal about avoiding or selling Apple. Experts like New Street's&nbsp;Pierre Ferragu&nbsp;and Satori Fund's&nbsp;Dan Niles&nbsp;are the few that come to mind, and their theses seem to align pretty well with every other bearish call on AAPL that I have seen recently.</p><p><blockquote>没有多少分析师和投资组合经理公开表示要避免或出售苹果。像New Street的Pierre Ferragu和Satori Fund的Dan Niles这样的专家是我想到的少数几个，他们的论点似乎与我最近看到的所有其他看跌AAPL的看涨期权非常一致。</blockquote></p><p> The first common reason to sell the stock is often phrased in different ways, but can effectively be summarized as follows: Apple's financial results in the near term should suffer from demand that has already turned into revenues in calendar 2020, during the thick of the pandemic and stay-at-home consumption wave. This is particularly true following the launch of the iPhone 13 that some (including legendary Apple founder&nbsp;Steve Wozniak) see as merely a minor upgrade from the previous model.</p><p><blockquote>出售股票的第一个常见原因通常以不同的方式表述，但可以有效地总结如下：苹果近期的财务业绩应该会受到需求的影响，而需求已经在2020年疫情最严重的时候转化为收入和居家消费浪潮。在iPhone 13发布之后尤其如此，一些人（包括传奇的苹果创始人Steve Wozniak）认为iPhone 13只是对上一款机型的小幅升级。</blockquote></p><p> I see the concern here, especially considering that Apple will start to face unsurmountable iPhone comps in the holidays and post-holiday quarters – see graph below. But the same chart also shows that there seemed to exist quite a bit of pent-up demand over the many quarters that preceded the iPhone 12 launch. One possible justification for this shift in sales from fiscal 2019-2020 to 2021 is Apple's late entry into the 5G space. Consumers that are loyal to or just prefer the iOS device probably waited patiently to upgrade or switch, and then they did it all at once.</p><p><blockquote>我看到了这里的担忧，特别是考虑到苹果将在假期和节后季度开始面临无法克服的iPhone竞争——见下图。但同一张图表还显示，在iPhone 12发布之前的许多季度中，似乎存在相当多被压抑的需求。销售额从2019-2020财年转移到2021财年的一个可能原因是苹果进入5G领域较晚。忠于或只是喜欢iOS设备的消费者可能会耐心等待升级或切换，然后他们一下子就完成了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7dc677f0a1c77dd39f40b4cc99c6fc15\" tg-width=\"460\" tg-height=\"322\" width=\"100%\" height=\"auto\"><span>Source: DM Martins Research, data from company reports</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：DM Martins Research，数据来自公司报告</span></p></blockquote></p><p> This may also help to explain, in part, why Apple's revenues in Greater China shot through the roof in the past 6 to 12 months. With the country's 5G infrastructure being further developed, owning a device that can handle the faster speeds probably makes most sense. Sales in the region had been lackluster to say the least since 2015, and dropped YOY by as much as 29% in fiscal Q4 of 2020. In the past three quarters, however, revenues climbed by at least 57% in each period.</p><p><blockquote>这也可能有助于部分解释为什么苹果在大中华区的收入在过去6至12个月内飙升。随着该国5G基础设施的进一步发展，拥有一款能够处理更快速度的设备可能是最有意义的。至少可以说，自2015年以来，该地区的销售额一直低迷，2020财年第四季度同比下降了29%。然而，在过去三个季度中，每个季度的收入都至少增长了57%。</blockquote></p><p> In the end, over the last 12 quarters – i.e. roughly the useful life of the average iPhone – Apple's smartphone sales have risen by only 4.8% per year. Considering that ASP (average selling price) has likely increased during the period, this figure barely represents any meaningful growth in device shipments over a full cycle. Therefore, to think that demand for Apple's products will fall off a cliff next seems like a stretch, especially if one also considers chip innovation and design updates in Mac and iPad.</p><p><blockquote>最终，在过去的12个季度（大约是iPhone的平均使用寿命）中，苹果的智能手机销量每年仅增长4.8%。考虑到ASP（平均售价）在此期间可能有所上涨，这一数字几乎不能代表整个周期内设备出货量的任何有意义的增长。因此，认为接下来对苹果产品的需求会断崖式下跌似乎有些牵强，特别是如果还考虑到Mac和iPad的芯片创新和设计更新的话。</blockquote></p><p> <b>Key risk #2: valuation</b></p><p><blockquote><b>关键风险#2：估值</b></blockquote></p><p> The other key risk of investing in Apple that is often brought up is valuation. Dan Niles, mentioned above, suggests that a next-year P/E of 26 times might not even be the biggest deal. The problem is that this multiple looks too rich against growth expectations that are modest.Analysts expect Apple's EPS&nbsp;to rise by only 4% per year through fiscal 2025. Alphabet (GOOG)(GOOGL), valued at a similar earnings multiple, is expected to drive earnings 16% higher per year over a similar period.</p><p><blockquote>投资苹果经常被提及的另一个主要风险是估值。上面提到的丹·奈尔斯(Dan Niles)表示，明年26倍的市盈率可能甚至不是最大的交易。问题是，与温和的增长预期相比，这个市盈率看起来太高了。分析师预计，到2025财年，苹果的每股收益每年仅增长4%。Alphabet(GOOG)（GOOGL）的市盈率相似，预计同期盈利每年将增长16%。</blockquote></p><p> That, in my view, is a more reasonable bearish argument. Per my estimates, Apple is by far the stock with the highest PEG ratio (P/E over long-term EPS growth) of 6.5 times. Amazon (AMZN) is a very distant second on this metric, at 2.3 times. But even here, I see a good argument to be made in favor of Apple.</p><p><blockquote>在我看来，这是一个更合理的看跌论点。根据我的估计，苹果是迄今为止PEG比率（市盈率超过长期每股收益增长）最高的股票，为6.5倍。亚马逊(AMZN)在这一指标上远远落后于第二名，为2.3倍。但即使在这里，我也看到了一个支持苹果的好理由。</blockquote></p><p></p><p> First, the company has been proving to be a powerful gatekeeper in the tech world. Here is one example: the first, most blatant sign that Apple's iOS privacy policy changes in the summer&nbsp;have been hurting social media companies&nbsp;and their financial statements&nbsp;led to the Nasdaqe&nbsp;rasing $120 billion in market value in a matter of minutes – most of which coming from internet stocks. Should one be expected to pay a premium for a stock in the face of such market control? I would say so.</p><p><blockquote>首先，该公司已被证明是科技界强大的看门人。这里有一个例子：第一个也是最明显的迹象表明，苹果今年夏天iOS隐私政策的变化一直在损害社交媒体公司，它们的财务报表导致纳斯达克在几分钟内市值飙升1200亿美元——其中大部分来自互联网股票。面对这种市场控制，人们应该为股票支付溢价吗？我会这么说。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0946db3f3bc62569a56f2dbe2aa75922\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Also, as the chart above depicts, Apple's forward-year P/E has certainly expanded relative to what it used to be a few years ago. But the multi-year move higher seems consistent with (1) a wave of increased demand for Apple's products and services, (2) better margins, (3) a drop in interest rates in 2020, and (4) a broad stock market that has become generally more expensive. Compared to how AAPL traded only about three months ago, P/E has in fact dipped about three turns and returned to early 2021 levels.</p><p><blockquote>此外，如上图所示，苹果的远期市盈率相对于几年前肯定有所扩大。但多年来的上涨似乎与(1)对苹果产品和服务的需求增加浪潮、(2)利润率提高、(3)2020年利率下降以及(4)广泛的股市一致市场普遍变得更加昂贵。与大约三个月前AAPL的交易方式相比，市盈率实际上已经下降了大约三圈，并回到了2021年初的水平。</blockquote></p><p> <b>Key risk #3: lack of positive catalysts</b></p><p><blockquote><b>关键风险#3：缺乏积极的催化剂</b></blockquote></p><p> The next risk to investing in Apple that is often cited are short-term catalysts. The iPhone 13 was announced a few weeks ago, and&nbsp;so has the refreshed lineup&nbsp;of MacBook Pro devices equipped with the new M1 Pro and Max chips. Fiscal fourth quarter earnings is also in the rearview mirror. In fact, I think that the drop off in relevant Apple news in the fourth quarter correlates well with a stock that, seasonally, tends to perform worse in the November-to-January period. Bears may also argue that, with a few quarters of tough comps ahead, investors might have a hard time finding reasons to buy AAPL in the next few months.</p><p><blockquote>经常提到的投资苹果的下一个风险是短期催化剂。iPhone 13在几周前发布，配备新M1 Pro和Max芯片的MacBook Pro设备的更新阵容也是如此。第四财季盈利也已成为过去。事实上，我认为第四季度相关苹果新闻的下降与一只股票在11月至1月期间季节性表现往往较差的股票密切相关。看空者还可能辩称，由于未来几个季度的业绩艰难，投资者可能很难在未来几个月内找到购买苹果公司的理由。</blockquote></p><p> But here, I believe that a bit of patience is warranted. First, the recent malaise in share price alone may be enough to attract new money from investors looking for a good deal on a high-quality stock. But more importantly, longer-term catalysts are likely to make more of a difference on share price and financial performance over the next, say, five years.</p><p><blockquote>但在这里，我认为需要一点耐心。首先，仅最近股价的低迷就足以吸引寻求优质股票优惠的投资者的新资金。但更重要的是，长期催化剂可能会在未来五年内对股价和财务业绩产生更大影响。</blockquote></p><p> I have previously talked in more detail about two catalysts that quickly come to mind. I doubt that much upside from initiatives like mixed reality and&nbsp;autonomous vehicle&nbsp;has been factored into analysts' financial models – and hence, properly priced into the stock. Because Apple is run by a conservative team of executives, I bet that both massive growth opportunities will be pursued if and when they are accretive to the company's earnings. They should, therefore, serve as the key catalysts driving long-term growth expectations (which is relevant for risk #1 above) and share price higher.</p><p><blockquote>我之前已经更详细地谈到了两个很快浮现在脑海中的催化剂。我怀疑混合现实和自动驾驶汽车等举措的太大好处是否已纳入分析师的财务模型，因此也无法正确定价到股票中。由于苹果是由一个保守的高管团队运营的，我敢打赌，如果这两个巨大的增长机会能够增加公司的盈利，那么它们就会被追求。因此，它们应该成为推动长期增长预期（与上述风险#1相关）和股价上涨的关键催化剂。</blockquote></p><p> <b>In summary</b></p><p><blockquote><b>总之</b></blockquote></p><p> Apple may not be the same pound-the-table opportunity that I believed it to be&nbsp;in February 2021&nbsp;or, better yet,in April 2018&nbsp;– in both cases, I believed that shares had sold off for no good reason. But I continue to think that AAPL is a stock to own today through the next several years, especially now that the earnings multiple has started to rerate towards year-ago levels. Should Apple continue to head lower in the near term, the pullback (assuming no meaningful change in business fundamentals) would present an even better chance to buy.</p><p><blockquote>苹果可能不像我在2021年2月或更好的2018年4月那样是一个巨大的机会——在这两种情况下，我都认为股票毫无理由地遭到抛售。但我仍然认为，苹果公司是一只值得在未来几年持有的股票，尤其是现在市盈率已开始重估至去年同期的水平。如果苹果短期内继续走低，回调（假设商业基本面没有发生有意义的变化）将提供更好的买入机会。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple: The Bear Argument, And Why It's Wrong<blockquote>苹果：熊市论点及其错误的原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple: The Bear Argument, And Why It's Wrong<blockquote>苹果：熊市论点及其错误的原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-11-13 08:47</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.</li>  <li>I list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.</li>  <li>Maybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4bc955cc5d27328c3b89b327b9368d27\" tg-width=\"1536\" tg-height=\"1020\" width=\"100%\" height=\"auto\"><span>kmwphotography/iStock via Getty Images</span></p><p><blockquote><ul><li>苹果未能长期保持在每股150美元以上，空头开始关注近期价格的疲软。</li><li>我列出了几个最流行的看跌论点，并解释了为什么我认为它们要么是短视的，要么很可能是不正确的。</li><li>也许苹果公司并不是同样值得买入的股票，但我仍然认为这是一只今天值得在未来几年持有的股票。</li></ul><p class=\"t-img-caption\"><span>kmwphotography/iStock来自Getty Images</span></p></blockquote></p><p> With Apple (AAPL) once again failing to make fresh all-time highs, now down around 6% from the peak and dipping closer towards key moving-average support, bears have started to pay attention. Still, I think that the case for selling (or shorting) this stock does not hold much water in the long term, and I believe that bears will ultimately tire of swimming against the current.</p><p><blockquote>随着苹果(AAPL)再次未能创下历史新高，目前较峰值下跌约6%，并接近关键移动平均线支撑位，空头开始关注。尽管如此，我认为从长远来看，出售（或做空）这只股票的理由并不成立，而且我相信空头最终会厌倦逆流而上。</blockquote></p><p> Below, I list the most common few reasons why one might want to dump or stay away from Apple shares – and why I think that the bearish case is either short-sighted or most likely incorrect.</p><p><blockquote>下面，我列出了人们可能想要抛售或远离苹果股票的几个最常见的原因，以及为什么我认为看跌情况要么是短视的，要么很可能是不正确的。</blockquote></p><p> <b>Key risk #1: drop-off in demand</b></p><p><blockquote><b>关键风险#1：需求下降</b></blockquote></p><p> Not many analysts and portfolio managers have been vocal about avoiding or selling Apple. Experts like New Street's&nbsp;Pierre Ferragu&nbsp;and Satori Fund's&nbsp;Dan Niles&nbsp;are the few that come to mind, and their theses seem to align pretty well with every other bearish call on AAPL that I have seen recently.</p><p><blockquote>没有多少分析师和投资组合经理公开表示要避免或出售苹果。像New Street的Pierre Ferragu和Satori Fund的Dan Niles这样的专家是我想到的少数几个，他们的论点似乎与我最近看到的所有其他看跌AAPL的看涨期权非常一致。</blockquote></p><p> The first common reason to sell the stock is often phrased in different ways, but can effectively be summarized as follows: Apple's financial results in the near term should suffer from demand that has already turned into revenues in calendar 2020, during the thick of the pandemic and stay-at-home consumption wave. This is particularly true following the launch of the iPhone 13 that some (including legendary Apple founder&nbsp;Steve Wozniak) see as merely a minor upgrade from the previous model.</p><p><blockquote>出售股票的第一个常见原因通常以不同的方式表述，但可以有效地总结如下：苹果近期的财务业绩应该会受到需求的影响，而需求已经在2020年疫情最严重的时候转化为收入和居家消费浪潮。在iPhone 13发布之后尤其如此，一些人（包括传奇的苹果创始人Steve Wozniak）认为iPhone 13只是对上一款机型的小幅升级。</blockquote></p><p> I see the concern here, especially considering that Apple will start to face unsurmountable iPhone comps in the holidays and post-holiday quarters – see graph below. But the same chart also shows that there seemed to exist quite a bit of pent-up demand over the many quarters that preceded the iPhone 12 launch. One possible justification for this shift in sales from fiscal 2019-2020 to 2021 is Apple's late entry into the 5G space. Consumers that are loyal to or just prefer the iOS device probably waited patiently to upgrade or switch, and then they did it all at once.</p><p><blockquote>我看到了这里的担忧，特别是考虑到苹果将在假期和节后季度开始面临无法克服的iPhone竞争——见下图。但同一张图表还显示，在iPhone 12发布之前的许多季度中，似乎存在相当多被压抑的需求。销售额从2019-2020财年转移到2021财年的一个可能原因是苹果进入5G领域较晚。忠于或只是喜欢iOS设备的消费者可能会耐心等待升级或切换，然后他们一下子就完成了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7dc677f0a1c77dd39f40b4cc99c6fc15\" tg-width=\"460\" tg-height=\"322\" width=\"100%\" height=\"auto\"><span>Source: DM Martins Research, data from company reports</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：DM Martins Research，数据来自公司报告</span></p></blockquote></p><p> This may also help to explain, in part, why Apple's revenues in Greater China shot through the roof in the past 6 to 12 months. With the country's 5G infrastructure being further developed, owning a device that can handle the faster speeds probably makes most sense. Sales in the region had been lackluster to say the least since 2015, and dropped YOY by as much as 29% in fiscal Q4 of 2020. In the past three quarters, however, revenues climbed by at least 57% in each period.</p><p><blockquote>这也可能有助于部分解释为什么苹果在大中华区的收入在过去6至12个月内飙升。随着该国5G基础设施的进一步发展，拥有一款能够处理更快速度的设备可能是最有意义的。至少可以说，自2015年以来，该地区的销售额一直低迷，2020财年第四季度同比下降了29%。然而，在过去三个季度中，每个季度的收入都至少增长了57%。</blockquote></p><p> In the end, over the last 12 quarters – i.e. roughly the useful life of the average iPhone – Apple's smartphone sales have risen by only 4.8% per year. Considering that ASP (average selling price) has likely increased during the period, this figure barely represents any meaningful growth in device shipments over a full cycle. Therefore, to think that demand for Apple's products will fall off a cliff next seems like a stretch, especially if one also considers chip innovation and design updates in Mac and iPad.</p><p><blockquote>最终，在过去的12个季度（大约是iPhone的平均使用寿命）中，苹果的智能手机销量每年仅增长4.8%。考虑到ASP（平均售价）在此期间可能有所上涨，这一数字几乎不能代表整个周期内设备出货量的任何有意义的增长。因此，认为接下来对苹果产品的需求会断崖式下跌似乎有些牵强，特别是如果还考虑到Mac和iPad的芯片创新和设计更新的话。</blockquote></p><p> <b>Key risk #2: valuation</b></p><p><blockquote><b>关键风险#2：估值</b></blockquote></p><p> The other key risk of investing in Apple that is often brought up is valuation. Dan Niles, mentioned above, suggests that a next-year P/E of 26 times might not even be the biggest deal. The problem is that this multiple looks too rich against growth expectations that are modest.Analysts expect Apple's EPS&nbsp;to rise by only 4% per year through fiscal 2025. Alphabet (GOOG)(GOOGL), valued at a similar earnings multiple, is expected to drive earnings 16% higher per year over a similar period.</p><p><blockquote>投资苹果经常被提及的另一个主要风险是估值。上面提到的丹·奈尔斯(Dan Niles)表示，明年26倍的市盈率可能甚至不是最大的交易。问题是，与温和的增长预期相比，这个市盈率看起来太高了。分析师预计，到2025财年，苹果的每股收益每年仅增长4%。Alphabet(GOOG)（GOOGL）的市盈率相似，预计同期盈利每年将增长16%。</blockquote></p><p> That, in my view, is a more reasonable bearish argument. Per my estimates, Apple is by far the stock with the highest PEG ratio (P/E over long-term EPS growth) of 6.5 times. Amazon (AMZN) is a very distant second on this metric, at 2.3 times. But even here, I see a good argument to be made in favor of Apple.</p><p><blockquote>在我看来，这是一个更合理的看跌论点。根据我的估计，苹果是迄今为止PEG比率（市盈率超过长期每股收益增长）最高的股票，为6.5倍。亚马逊(AMZN)在这一指标上远远落后于第二名，为2.3倍。但即使在这里，我也看到了一个支持苹果的好理由。</blockquote></p><p></p><p> First, the company has been proving to be a powerful gatekeeper in the tech world. Here is one example: the first, most blatant sign that Apple's iOS privacy policy changes in the summer&nbsp;have been hurting social media companies&nbsp;and their financial statements&nbsp;led to the Nasdaqe&nbsp;rasing $120 billion in market value in a matter of minutes – most of which coming from internet stocks. Should one be expected to pay a premium for a stock in the face of such market control? I would say so.</p><p><blockquote>首先，该公司已被证明是科技界强大的看门人。这里有一个例子：第一个也是最明显的迹象表明，苹果今年夏天iOS隐私政策的变化一直在损害社交媒体公司，它们的财务报表导致纳斯达克在几分钟内市值飙升1200亿美元——其中大部分来自互联网股票。面对这种市场控制，人们应该为股票支付溢价吗？我会这么说。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0946db3f3bc62569a56f2dbe2aa75922\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Also, as the chart above depicts, Apple's forward-year P/E has certainly expanded relative to what it used to be a few years ago. But the multi-year move higher seems consistent with (1) a wave of increased demand for Apple's products and services, (2) better margins, (3) a drop in interest rates in 2020, and (4) a broad stock market that has become generally more expensive. Compared to how AAPL traded only about three months ago, P/E has in fact dipped about three turns and returned to early 2021 levels.</p><p><blockquote>此外，如上图所示，苹果的远期市盈率相对于几年前肯定有所扩大。但多年来的上涨似乎与(1)对苹果产品和服务的需求增加浪潮、(2)利润率提高、(3)2020年利率下降以及(4)广泛的股市一致市场普遍变得更加昂贵。与大约三个月前AAPL的交易方式相比，市盈率实际上已经下降了大约三圈，并回到了2021年初的水平。</blockquote></p><p> <b>Key risk #3: lack of positive catalysts</b></p><p><blockquote><b>关键风险#3：缺乏积极的催化剂</b></blockquote></p><p> The next risk to investing in Apple that is often cited are short-term catalysts. The iPhone 13 was announced a few weeks ago, and&nbsp;so has the refreshed lineup&nbsp;of MacBook Pro devices equipped with the new M1 Pro and Max chips. Fiscal fourth quarter earnings is also in the rearview mirror. In fact, I think that the drop off in relevant Apple news in the fourth quarter correlates well with a stock that, seasonally, tends to perform worse in the November-to-January period. Bears may also argue that, with a few quarters of tough comps ahead, investors might have a hard time finding reasons to buy AAPL in the next few months.</p><p><blockquote>经常提到的投资苹果的下一个风险是短期催化剂。iPhone 13在几周前发布，配备新M1 Pro和Max芯片的MacBook Pro设备的更新阵容也是如此。第四财季盈利也已成为过去。事实上，我认为第四季度相关苹果新闻的下降与一只股票在11月至1月期间季节性表现往往较差的股票密切相关。看空者还可能辩称，由于未来几个季度的业绩艰难，投资者可能很难在未来几个月内找到购买苹果公司的理由。</blockquote></p><p> But here, I believe that a bit of patience is warranted. First, the recent malaise in share price alone may be enough to attract new money from investors looking for a good deal on a high-quality stock. But more importantly, longer-term catalysts are likely to make more of a difference on share price and financial performance over the next, say, five years.</p><p><blockquote>但在这里，我认为需要一点耐心。首先，仅最近股价的低迷就足以吸引寻求优质股票优惠的投资者的新资金。但更重要的是，长期催化剂可能会在未来五年内对股价和财务业绩产生更大影响。</blockquote></p><p> I have previously talked in more detail about two catalysts that quickly come to mind. I doubt that much upside from initiatives like mixed reality and&nbsp;autonomous vehicle&nbsp;has been factored into analysts' financial models – and hence, properly priced into the stock. Because Apple is run by a conservative team of executives, I bet that both massive growth opportunities will be pursued if and when they are accretive to the company's earnings. They should, therefore, serve as the key catalysts driving long-term growth expectations (which is relevant for risk #1 above) and share price higher.</p><p><blockquote>我之前已经更详细地谈到了两个很快浮现在脑海中的催化剂。我怀疑混合现实和自动驾驶汽车等举措的太大好处是否已纳入分析师的财务模型，因此也无法正确定价到股票中。由于苹果是由一个保守的高管团队运营的，我敢打赌，如果这两个巨大的增长机会能够增加公司的盈利，那么它们就会被追求。因此，它们应该成为推动长期增长预期（与上述风险#1相关）和股价上涨的关键催化剂。</blockquote></p><p> <b>In summary</b></p><p><blockquote><b>总之</b></blockquote></p><p> Apple may not be the same pound-the-table opportunity that I believed it to be&nbsp;in February 2021&nbsp;or, better yet,in April 2018&nbsp;– in both cases, I believed that shares had sold off for no good reason. But I continue to think that AAPL is a stock to own today through the next several years, especially now that the earnings multiple has started to rerate towards year-ago levels. Should Apple continue to head lower in the near term, the pullback (assuming no meaningful change in business fundamentals) would present an even better chance to buy.</p><p><blockquote>苹果可能不像我在2021年2月或更好的2018年4月那样是一个巨大的机会——在这两种情况下，我都认为股票毫无理由地遭到抛售。但我仍然认为，苹果公司是一只值得在未来几年持有的股票，尤其是现在市盈率已开始重估至去年同期的水平。如果苹果短期内继续走低，回调（假设商业基本面没有发生有意义的变化）将提供更好的买入机会。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4468890-apple-the-bear-argument-and-why-its-wrong\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4468890-apple-the-bear-argument-and-why-its-wrong","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129004768","content_text":"Summary\n\nApple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.\nI list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.\nMaybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.\n\nkmwphotography/iStock via Getty Images\nWith Apple (AAPL) once again failing to make fresh all-time highs, now down around 6% from the peak and dipping closer towards key moving-average support, bears have started to pay attention. Still, I think that the case for selling (or shorting) this stock does not hold much water in the long term, and I believe that bears will ultimately tire of swimming against the current.\nBelow, I list the most common few reasons why one might want to dump or stay away from Apple shares – and why I think that the bearish case is either short-sighted or most likely incorrect.\nKey risk #1: drop-off in demand\nNot many analysts and portfolio managers have been vocal about avoiding or selling Apple. Experts like New Street's Pierre Ferragu and Satori Fund's Dan Niles are the few that come to mind, and their theses seem to align pretty well with every other bearish call on AAPL that I have seen recently.\nThe first common reason to sell the stock is often phrased in different ways, but can effectively be summarized as follows: Apple's financial results in the near term should suffer from demand that has already turned into revenues in calendar 2020, during the thick of the pandemic and stay-at-home consumption wave. This is particularly true following the launch of the iPhone 13 that some (including legendary Apple founder Steve Wozniak) see as merely a minor upgrade from the previous model.\nI see the concern here, especially considering that Apple will start to face unsurmountable iPhone comps in the holidays and post-holiday quarters – see graph below. But the same chart also shows that there seemed to exist quite a bit of pent-up demand over the many quarters that preceded the iPhone 12 launch. One possible justification for this shift in sales from fiscal 2019-2020 to 2021 is Apple's late entry into the 5G space. Consumers that are loyal to or just prefer the iOS device probably waited patiently to upgrade or switch, and then they did it all at once.\nSource: DM Martins Research, data from company reports\nThis may also help to explain, in part, why Apple's revenues in Greater China shot through the roof in the past 6 to 12 months. With the country's 5G infrastructure being further developed, owning a device that can handle the faster speeds probably makes most sense. Sales in the region had been lackluster to say the least since 2015, and dropped YOY by as much as 29% in fiscal Q4 of 2020. In the past three quarters, however, revenues climbed by at least 57% in each period.\nIn the end, over the last 12 quarters – i.e. roughly the useful life of the average iPhone – Apple's smartphone sales have risen by only 4.8% per year. Considering that ASP (average selling price) has likely increased during the period, this figure barely represents any meaningful growth in device shipments over a full cycle. Therefore, to think that demand for Apple's products will fall off a cliff next seems like a stretch, especially if one also considers chip innovation and design updates in Mac and iPad.\nKey risk #2: valuation\nThe other key risk of investing in Apple that is often brought up is valuation. Dan Niles, mentioned above, suggests that a next-year P/E of 26 times might not even be the biggest deal. The problem is that this multiple looks too rich against growth expectations that are modest.Analysts expect Apple's EPS to rise by only 4% per year through fiscal 2025. Alphabet (GOOG)(GOOGL), valued at a similar earnings multiple, is expected to drive earnings 16% higher per year over a similar period.\nThat, in my view, is a more reasonable bearish argument. Per my estimates, Apple is by far the stock with the highest PEG ratio (P/E over long-term EPS growth) of 6.5 times. Amazon (AMZN) is a very distant second on this metric, at 2.3 times. But even here, I see a good argument to be made in favor of Apple.\nFirst, the company has been proving to be a powerful gatekeeper in the tech world. Here is one example: the first, most blatant sign that Apple's iOS privacy policy changes in the summer have been hurting social media companies and their financial statements led to the Nasdaqe rasing $120 billion in market value in a matter of minutes – most of which coming from internet stocks. Should one be expected to pay a premium for a stock in the face of such market control? I would say so.\nData by YCharts\nAlso, as the chart above depicts, Apple's forward-year P/E has certainly expanded relative to what it used to be a few years ago. But the multi-year move higher seems consistent with (1) a wave of increased demand for Apple's products and services, (2) better margins, (3) a drop in interest rates in 2020, and (4) a broad stock market that has become generally more expensive. Compared to how AAPL traded only about three months ago, P/E has in fact dipped about three turns and returned to early 2021 levels.\nKey risk #3: lack of positive catalysts\nThe next risk to investing in Apple that is often cited are short-term catalysts. The iPhone 13 was announced a few weeks ago, and so has the refreshed lineup of MacBook Pro devices equipped with the new M1 Pro and Max chips. Fiscal fourth quarter earnings is also in the rearview mirror. In fact, I think that the drop off in relevant Apple news in the fourth quarter correlates well with a stock that, seasonally, tends to perform worse in the November-to-January period. Bears may also argue that, with a few quarters of tough comps ahead, investors might have a hard time finding reasons to buy AAPL in the next few months.\nBut here, I believe that a bit of patience is warranted. First, the recent malaise in share price alone may be enough to attract new money from investors looking for a good deal on a high-quality stock. But more importantly, longer-term catalysts are likely to make more of a difference on share price and financial performance over the next, say, five years.\nI have previously talked in more detail about two catalysts that quickly come to mind. I doubt that much upside from initiatives like mixed reality and autonomous vehicle has been factored into analysts' financial models – and hence, properly priced into the stock. Because Apple is run by a conservative team of executives, I bet that both massive growth opportunities will be pursued if and when they are accretive to the company's earnings. They should, therefore, serve as the key catalysts driving long-term growth expectations (which is relevant for risk #1 above) and share price higher.\nIn summary\nApple may not be the same pound-the-table opportunity that I believed it to be in February 2021 or, better yet,in April 2018 – in both cases, I believed that shares had sold off for no good reason. But I continue to think that AAPL is a stock to own today through the next several years, especially now that the earnings multiple has started to rerate towards year-ago levels. Should Apple continue to head lower in the near term, the pullback (assuming no meaningful change in business fundamentals) would present an even better chance to buy.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873009947,"gmtCreate":1636783648651,"gmtModify":1636783648828,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873009947","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879342797,"gmtCreate":1636685219229,"gmtModify":1636685325469,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879342797","repostId":"1179335408","repostType":4,"isVote":1,"tweetType":1,"viewCount":1094,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":609468359,"gmtCreate":1638318245027,"gmtModify":1638318245250,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Hopefully today turn green&nbsp;","listText":"Hopefully today turn green&nbsp;","text":"Hopefully today turn green","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609468359","repostId":"1129769141","repostType":4,"repost":{"id":"1129769141","kind":"news","pubTimestamp":1638317199,"share":"https://www.laohu8.com/m/news/1129769141?lang=zh_CN&edition=full","pubTime":"2021-12-01 08:06","market":"us","language":"en","title":"Oversold Singapore Bourse Called Lower Again<blockquote>超卖的新加坡证券交易所再次下调</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129769141","media":"RTTNews","summary":"The Singapore stock market has finished lower in six straight trading days, sinking almost 200 point","content":"<p>The Singapore stock market has finished lower in six straight trading days, sinking almost 200 points or 6.4 percent along the way. The Straits Times Index now sits just above the 3,040-point plateau and it's got another weak lead for Wednesday's trade.</p><p><blockquote>新加坡股市连续六个交易日收低，跌幅近200点，跌幅6.4%。海峡时报指数目前略高于3,040点的高位，周三的交易再次小幅领先。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;suggests consolidation on continued COVID-19 worries and concerns over the outlook for interest rates. The European and U.S. markets were down and the Asian markets figure to open in similar fashion.</p><p><blockquote>对亚洲市场的全球预测表明，对新冠肺炎的持续担忧和对利率前景的担忧将会巩固。欧洲和美国市场下跌，亚洲市场预计也将以类似的方式开盘。</blockquote></p><p> The STI finished sharply lower on Tuesday with damage across the board, especially from the financials and industrials.</p><p><blockquote>海指周二大幅收低，全线受损，尤其是金融和工业股。</blockquote></p><p> For the day, the index plunged 79.29 points or 2.54 percent to finish at the daily low of 3,041.29 after peaking at 3,129.54. Volume was 3.22 billion shares worth 3.89 billion Singapore dollars. There were 338 decliners and 172 gainers.</p><p><blockquote>当天，该指数暴跌79.29点或2.54%，收于3,041.29点的日低，此前曾触及3,129.54点。成交量为32.2亿股，价值38.9亿新元。下跌股338家，上涨股172家。</blockquote></p><p> Among the actives, Ascendas REIT slumped 2.34 percent, while CapitaLand Integrated Commercial Trust and Jardine Cycle both fell 1.40 percent, City Developments added 0.29 percent, Comfort DelGro plummeted 4.20 percent, Dairy Farm International and Thai Beverage both weakened 2.19 percent, DBS Group declined 2.99 percent, Genting Singapore skidded 2.53 percent, Keppel Corp sank 2.11 percent, Mapletree Commercial Trust stumbled 2.39 percent, Mapletree Logistics Trust lost 1.87 percent, Oversea-Chinese Banking Corporation surrendered 3.17 percent, SATS retreated 2.56 percent, SembCorp Industries plunged 4.08 percent, Singapore Airlines slid 0.81 percent, Singapore Exchange tumbled 3.25 percent, Singapore Press Holdings eased 0.43 percent, Singapore Technologies Engineering was down 0.78 percent, SingTel dropped 2.07 percent, United Overseas Bank tanked 4.00 percent, Wilmar International shed 1.91 percent and Yangzijiang Shipbuilding was unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌2.34%，凯德综合商业信托和怡和周期均下跌1.40%，城市发展上涨0.29%，舒适德尔高暴跌4.20%，乳业国际和泰国饮料均下跌2.19%，星展集团下跌2.99%，云顶新加坡下跌2.53%，吉宝企业下跌2.11%，丰树商业信托下跌2.39%，丰树物流信托下跌1.87%，华侨银行下跌3.17%，胜科工业下跌4.08%，新加坡航空下跌0.81%，新加坡科技工程下跌0.78%，新加坡电信下跌2.07%，丰益国际下跌1.91%，扬子江造船持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened lower on Tuesday and remained largely under water throughout the trading day.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周二开盘走低，整个交易日基本保持在水下。</blockquote></p><p></p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oversold Singapore Bourse Called Lower Again<blockquote>超卖的新加坡证券交易所再次下调</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOversold Singapore Bourse Called Lower Again<blockquote>超卖的新加坡证券交易所再次下调</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">RTTNews</strong><span class=\"h-time small\">2021-12-01 08:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The Singapore stock market has finished lower in six straight trading days, sinking almost 200 points or 6.4 percent along the way. The Straits Times Index now sits just above the 3,040-point plateau and it's got another weak lead for Wednesday's trade.</p><p><blockquote>新加坡股市连续六个交易日收低，跌幅近200点，跌幅6.4%。海峡时报指数目前略高于3,040点的高位，周三的交易再次小幅领先。</blockquote></p><p> The global forecast for the Asian&nbsp;markets&nbsp;suggests consolidation on continued COVID-19 worries and concerns over the outlook for interest rates. The European and U.S. markets were down and the Asian markets figure to open in similar fashion.</p><p><blockquote>对亚洲市场的全球预测表明，对新冠肺炎的持续担忧和对利率前景的担忧将会巩固。欧洲和美国市场下跌，亚洲市场预计也将以类似的方式开盘。</blockquote></p><p> The STI finished sharply lower on Tuesday with damage across the board, especially from the financials and industrials.</p><p><blockquote>海指周二大幅收低，全线受损，尤其是金融和工业股。</blockquote></p><p> For the day, the index plunged 79.29 points or 2.54 percent to finish at the daily low of 3,041.29 after peaking at 3,129.54. Volume was 3.22 billion shares worth 3.89 billion Singapore dollars. There were 338 decliners and 172 gainers.</p><p><blockquote>当天，该指数暴跌79.29点或2.54%，收于3,041.29点的日低，此前曾触及3,129.54点。成交量为32.2亿股，价值38.9亿新元。下跌股338家，上涨股172家。</blockquote></p><p> Among the actives, Ascendas REIT slumped 2.34 percent, while CapitaLand Integrated Commercial Trust and Jardine Cycle both fell 1.40 percent, City Developments added 0.29 percent, Comfort DelGro plummeted 4.20 percent, Dairy Farm International and Thai Beverage both weakened 2.19 percent, DBS Group declined 2.99 percent, Genting Singapore skidded 2.53 percent, Keppel Corp sank 2.11 percent, Mapletree Commercial Trust stumbled 2.39 percent, Mapletree Logistics Trust lost 1.87 percent, Oversea-Chinese Banking Corporation surrendered 3.17 percent, SATS retreated 2.56 percent, SembCorp Industries plunged 4.08 percent, Singapore Airlines slid 0.81 percent, Singapore Exchange tumbled 3.25 percent, Singapore Press Holdings eased 0.43 percent, Singapore Technologies Engineering was down 0.78 percent, SingTel dropped 2.07 percent, United Overseas Bank tanked 4.00 percent, Wilmar International shed 1.91 percent and Yangzijiang Shipbuilding was unchanged.</p><p><blockquote>活跃股中，腾飞房地产投资信托下跌2.34%，凯德综合商业信托和怡和周期均下跌1.40%，城市发展上涨0.29%，舒适德尔高暴跌4.20%，乳业国际和泰国饮料均下跌2.19%，星展集团下跌2.99%，云顶新加坡下跌2.53%，吉宝企业下跌2.11%，丰树商业信托下跌2.39%，丰树物流信托下跌1.87%，华侨银行下跌3.17%，胜科工业下跌4.08%，新加坡航空下跌0.81%，新加坡科技工程下跌0.78%，新加坡电信下跌2.07%，丰益国际下跌1.91%，扬子江造船持平。</blockquote></p><p> The lead from Wall Street is broadly negative as the major averages opened lower on Tuesday and remained largely under water throughout the trading day.</p><p><blockquote>华尔街的领先优势普遍为负面，主要股指周二开盘走低，整个交易日基本保持在水下。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.rttnews.com/3245823/oversold-singapore-bourse-called-lower-again.aspx?type=acom\">RTTNews</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"C6L.SI":"新加坡航空公司","BVA.SI":"顶级手套有限公司","STI.SI":"富时新加坡海峡指数","O39.SI":"华侨银行","D05.SI":"星展集团控股"},"source_url":"https://www.rttnews.com/3245823/oversold-singapore-bourse-called-lower-again.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129769141","content_text":"The Singapore stock market has finished lower in six straight trading days, sinking almost 200 points or 6.4 percent along the way. The Straits Times Index now sits just above the 3,040-point plateau and it's got another weak lead for Wednesday's trade.\nThe global forecast for the Asian markets suggests consolidation on continued COVID-19 worries and concerns over the outlook for interest rates. The European and U.S. markets were down and the Asian markets figure to open in similar fashion.\nThe STI finished sharply lower on Tuesday with damage across the board, especially from the financials and industrials.\nFor the day, the index plunged 79.29 points or 2.54 percent to finish at the daily low of 3,041.29 after peaking at 3,129.54. Volume was 3.22 billion shares worth 3.89 billion Singapore dollars. There were 338 decliners and 172 gainers.\nAmong the actives, Ascendas REIT slumped 2.34 percent, while CapitaLand Integrated Commercial Trust and Jardine Cycle both fell 1.40 percent, City Developments added 0.29 percent, Comfort DelGro plummeted 4.20 percent, Dairy Farm International and Thai Beverage both weakened 2.19 percent, DBS Group declined 2.99 percent, Genting Singapore skidded 2.53 percent, Keppel Corp sank 2.11 percent, Mapletree Commercial Trust stumbled 2.39 percent, Mapletree Logistics Trust lost 1.87 percent, Oversea-Chinese Banking Corporation surrendered 3.17 percent, SATS retreated 2.56 percent, SembCorp Industries plunged 4.08 percent, Singapore Airlines slid 0.81 percent, Singapore Exchange tumbled 3.25 percent, Singapore Press Holdings eased 0.43 percent, Singapore Technologies Engineering was down 0.78 percent, SingTel dropped 2.07 percent, United Overseas Bank tanked 4.00 percent, Wilmar International shed 1.91 percent and Yangzijiang Shipbuilding was unchanged.\nThe lead from Wall Street is broadly negative as the major averages opened lower on Tuesday and remained largely under water throughout the trading day.","news_type":1,"symbols_score_info":{"D05.SI":0.9,"STI.SI":0.9,"C6L.SI":0.9,"BVA.SI":0.9,"O39.SI":0.9}},"isVote":1,"tweetType":1,"viewCount":2426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873009947,"gmtCreate":1636783648651,"gmtModify":1636783648828,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873009947","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其努力分为与BioNTech在疫苗上的合作和对新冠肺炎药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600070485,"gmtCreate":1638023358779,"gmtModify":1638023358976,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600070485","repostId":"2186344334","repostType":4,"isVote":1,"tweetType":1,"viewCount":2696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879342797,"gmtCreate":1636685219229,"gmtModify":1636685325469,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879342797","repostId":"1179335408","repostType":4,"isVote":1,"tweetType":1,"viewCount":1094,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604455354,"gmtCreate":1639441217413,"gmtModify":1639441217858,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Yea&nbsp;","listText":"Yea&nbsp;","text":"Yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604455354","repostId":"2191098415","repostType":2,"repost":{"id":"2191098415","kind":"news","pubTimestamp":1639431600,"share":"https://www.laohu8.com/m/news/2191098415?lang=zh_CN&edition=full","pubTime":"2021-12-14 05:40","market":"sh","language":"zh","title":"外媒头条：美联储可能上演历史罕见鹰派转变","url":"https://stock-news.laohu8.com/highlight/detail?id=2191098415","media":"市场资讯","summary":"　　纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。　　这一结果凸显出近期令美联储和大多数经济学家感到意外的通胀飙升的不可预测性。美联储可能在即将召开的政策会议上宣布加快减码债券收购的步伐。　　经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。","content":"<p><b>全球财经媒体昨夜今晨共同关注的头条新闻主要有：</b></p>\n<blockquote>\n <b>1、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高</b>\n</blockquote>\n<blockquote>\n <b>2、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变</b>\n</blockquote>\n<blockquote>\n <b>3、<a href=\"https://laohu8.com/S/TSLA\">特斯拉</a>CEO埃隆·马斯克当选时代杂志2021年度风云人物</b>\n</blockquote>\n<blockquote>\n <b>4、牛津大学：omicron毒株能削弱两针<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>或<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>疫苗的保护力</b>\n</blockquote>\n<blockquote>\n <b>5、七国集团财长承诺解决供应链问题并避免未来重演</b>\n</blockquote>\n<blockquote>\n <b>6、小摩预计美失业率明年将降至3%左右&nbsp;奥密克戎是就业市场主要风险</b>\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/ce56c82d6c11f45604012124909fbdc4\" tg-width=\"550\" tg-height=\"313\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高</b></p>\n<p>纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。</p>\n<p>调查还显示，三年通胀预期自6月以来首次下降，达到4%，主要是受到无大学学历受访者的预期推动。然而，无论是短期还是长期，通胀的不确定性水平都在上升，并且都达到了历史新高。</p>\n<p>这一结果凸显出近期令美联储和大多数经济学家感到意外的通胀飙升的不可预测性。美联储可能在即将召开的政策会议上宣布加快减码债券收购的步伐。</p>\n<p>调查还显示，消费者对经济的乐观程度下降。</p>\n<p>调查显示，美国未来一年失业率上升的平均概率提高了0.6个百分点。11月受访者对与一年前相比家庭当前财务状况的看法有所恶化，更多受访者称财务状况变差。</p>\n<p><img src=\"https://static.tigerbbs.com/ad8e2ae248c8736422a112e3a316d6b9\" tg-width=\"550\" tg-height=\"310\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>加速减码+预告加息 美联储可能上演历史罕见的鹰派转变</b></p>\n<p>经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。</p>\n<p>超过一半的受访者预计，美联储周三结束两天政策会议后发布的季度预测将显示，18位官员的中值预测是明年加息两次。</p>\n<p>这与他们9月份的预测相比有变化。当时，决策者在2022年或2023年首次加息的预测上平分秋色。</p>\n<p>“这将是点阵图历史上最大的鹰派转变，”Macropolicy Perspectives高级经济学家Laura Rosner-Warburton表示。美联储自2012年开始发布利率预测的点阵图。</p>\n<p><img src=\"https://n.sinaimg.cn/tech/transform/395/w512h683/20211213/2dd2-a526974a89f50d8229b23ab688835d45.png\" tg-width=\"512\" tg-height=\"683\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物</b></p>\n<p>据报道，特斯拉CEO埃隆·马斯克（Elon Musk）今日被美国《时代》杂志评为“2021年度风云人物”。</p>\n<p>《时代》杂志称，作为世界上最富有的人，他没有房子，最近一直在抛售财产。他将卫星送入轨道，并利用<a href=\"https://laohu8.com/S/000591\">太阳能</a>服务千家万户。他驾驶着一辆自己制造的汽车，不需要汽油，也几乎不需要司机。他的手指一挥，股市就会暴涨或暴跌。他的每一句话都被一大群粉丝挂在嘴边。当他把业务推向全球时，还梦想着移民火星。</p>\n<p><img src=\"https://static.tigerbbs.com/4133304c52fa226b469ba60f980192f1\" tg-width=\"550\" tg-height=\"310\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力</b></p>\n<p>研究人员发现，正如人们所担忧的一样，omicron变异株削弱了辉瑞和阿斯利康两剂新冠疫苗所能提供的保护力，增加了接种者感染风险。</p>\n<p>牛津大学研究人员周一在一份报告中表示，在对接种辉瑞或阿斯利康疫苗的人采集的血液样本中，经检测新毒株omicron令中和抗体大幅减少，尤其是和德尔塔毒株相比，降幅很明显。</p>\n<p>阿斯利康疫苗的创造者之一Teresa Lambe表示，在接下来的几周，omicron的影响应该会得到更好的记录，以明确是否需要接种新疫苗。</p>\n<p>“我们希望当前的疫苗能够预防严重疾病和住院治疗”，Lambe表示。 “我们和其他疫苗生产商的立场是，如果需要一种针对新毒株的疫苗，我们可以快速推进。”</p>\n<p><img src=\"https://static.tigerbbs.com/7eb99a948e8b987f3e2c4401c8f7e901\" tg-width=\"550\" tg-height=\"309\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>七国集团财长承诺解决供应链问题并避免未来重演</b></p>\n<p>七国集团财长承诺加强合作，以解决造成商品短缺和通胀飙升的全球供应链问题。</p>\n<p>由于运输问题导致供应中断，零部件制成品短缺以及疫情造成能源价格上涨，全球消费者价格都在飙升。美国通胀率已触及1982年以来的最高水平，欧元区通胀率达到了创纪录的4.9%。</p>\n<p>在七国集团财长和央行行长会议的最后公报中，轮值主席国英国的财政大臣Rishi Sunak称，该组织将着眼于预测并避免未来的供应紧张。</p>\n<p>英国财政部表示，七国集团财长和央行行长们“就如何提高供应链韧性以及如何更准确地预测未来可能发生的干扰交换了看法”。</p>\n<p><img src=\"https://static.tigerbbs.com/5d92536ec41518383402813fee58b8bc\" tg-width=\"550\" tg-height=\"407\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p><b>小摩预计美失业率明年将降至3%左右&nbsp;奥密克戎是就业市场主要风险</b></p>\n<p><a href=\"https://laohu8.com/S/JPM\">摩根大通</a>首席美国经济学家Michael Feroli认为，2022年美国失业率将下降。</p>\n<p>“我认为到2022年底可以看到失业率在3%左右，”Feroli称。“过去五个月的失业率下降幅度令人深刻印象。我们预计下降速度会放缓，但很快就会降至4%以下。”</p>\n<p>在Feroli看来，随着雇主寻找人才以推动企业从疫情中复苏，就业市场可能会以良好的势头进入2022年。</p>\n<p>Feroli还预计，明年美国GDP将增长3%。他认为，美联储将在9月开始加息以抵消通胀，而通胀在一定程度上是由于劳动力市场状况吃紧。</p>\n<p>此外，就业市场的一个主要风险仍然是奥密克戎变体及其是否会减缓企业的招聘计划。</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>外媒头条：美联储可能上演历史罕见鹰派转变</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n外媒头条：美联储可能上演历史罕见鹰派转变\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 05:40 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2021-12-14/doc-ikyakumx3975846.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高\n\n\n2、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变\n\n\n3、特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物\n\n\n4、牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力\n\n\n5、七国集团财长承诺解决供应链问题并避免未来重演\n\n\n6、小摩预计美失业率明年将...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-12-14/doc-ikyakumx3975846.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/02a85629f2a809e4eabd8677140a5f70","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","DJX":"1/100道琼斯","DDM":"2倍做多道指ETF-ProShares","OEX":"标普100","DXD":"两倍做空道琼30指数ETF-ProShares",".IXIC":"NASDAQ Composite","DOG":"道指ETF-ProShares做空","SQQQ":"纳指三倍做空ETF","UDOW":"三倍做多道指30ETF-ProShares",".SPX":"S&P 500 Index","UPRO":"三倍做多标普500ETF-ProShares","IVV":"标普500ETF-iShares","PSQ":"做空纳斯达克100指数ETF-ProShares","QQQ":"纳指100ETF","SH":"做空标普500-Proshares","SPXU":"三倍做空标普500ETF-ProShares",".DJI":"道琼斯","BK4534":"瑞士信贷持仓","SSO":"2倍做多标普500ETF-ProShares","TQQQ":"纳指三倍做多ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SDOW":"三倍做空道指30ETF-ProShares","SPY":"标普500ETF","BK4504":"桥水持仓","SDS":"两倍做空标普500 ETF-ProShares","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓","QID":"两倍做空纳斯达克指数ETF-ProShares"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-12-14/doc-ikyakumx3975846.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2191098415","content_text":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高\n\n\n2、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变\n\n\n3、特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物\n\n\n4、牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力\n\n\n5、七国集团财长承诺解决供应链问题并避免未来重演\n\n\n6、小摩预计美失业率明年将降至3%左右 奥密克戎是就业市场主要风险\n\n\n纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高\n纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。\n调查还显示，三年通胀预期自6月以来首次下降，达到4%，主要是受到无大学学历受访者的预期推动。然而，无论是短期还是长期，通胀的不确定性水平都在上升，并且都达到了历史新高。\n这一结果凸显出近期令美联储和大多数经济学家感到意外的通胀飙升的不可预测性。美联储可能在即将召开的政策会议上宣布加快减码债券收购的步伐。\n调查还显示，消费者对经济的乐观程度下降。\n调查显示，美国未来一年失业率上升的平均概率提高了0.6个百分点。11月受访者对与一年前相比家庭当前财务状况的看法有所恶化，更多受访者称财务状况变差。\n\n加速减码+预告加息 美联储可能上演历史罕见的鹰派转变\n经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。\n超过一半的受访者预计，美联储周三结束两天政策会议后发布的季度预测将显示，18位官员的中值预测是明年加息两次。\n这与他们9月份的预测相比有变化。当时，决策者在2022年或2023年首次加息的预测上平分秋色。\n“这将是点阵图历史上最大的鹰派转变，”Macropolicy Perspectives高级经济学家Laura Rosner-Warburton表示。美联储自2012年开始发布利率预测的点阵图。\n\n特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物\n据报道，特斯拉CEO埃隆·马斯克（Elon Musk）今日被美国《时代》杂志评为“2021年度风云人物”。\n《时代》杂志称，作为世界上最富有的人，他没有房子，最近一直在抛售财产。他将卫星送入轨道，并利用太阳能服务千家万户。他驾驶着一辆自己制造的汽车，不需要汽油，也几乎不需要司机。他的手指一挥，股市就会暴涨或暴跌。他的每一句话都被一大群粉丝挂在嘴边。当他把业务推向全球时，还梦想着移民火星。\n\n牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力\n研究人员发现，正如人们所担忧的一样，omicron变异株削弱了辉瑞和阿斯利康两剂新冠疫苗所能提供的保护力，增加了接种者感染风险。\n牛津大学研究人员周一在一份报告中表示，在对接种辉瑞或阿斯利康疫苗的人采集的血液样本中，经检测新毒株omicron令中和抗体大幅减少，尤其是和德尔塔毒株相比，降幅很明显。\n阿斯利康疫苗的创造者之一Teresa Lambe表示，在接下来的几周，omicron的影响应该会得到更好的记录，以明确是否需要接种新疫苗。\n“我们希望当前的疫苗能够预防严重疾病和住院治疗”，Lambe表示。 “我们和其他疫苗生产商的立场是，如果需要一种针对新毒株的疫苗，我们可以快速推进。”\n\n七国集团财长承诺解决供应链问题并避免未来重演\n七国集团财长承诺加强合作，以解决造成商品短缺和通胀飙升的全球供应链问题。\n由于运输问题导致供应中断，零部件制成品短缺以及疫情造成能源价格上涨，全球消费者价格都在飙升。美国通胀率已触及1982年以来的最高水平，欧元区通胀率达到了创纪录的4.9%。\n在七国集团财长和央行行长会议的最后公报中，轮值主席国英国的财政大臣Rishi Sunak称，该组织将着眼于预测并避免未来的供应紧张。\n英国财政部表示，七国集团财长和央行行长们“就如何提高供应链韧性以及如何更准确地预测未来可能发生的干扰交换了看法”。\n\n小摩预计美失业率明年将降至3%左右 奥密克戎是就业市场主要风险\n摩根大通首席美国经济学家Michael Feroli认为，2022年美国失业率将下降。\n“我认为到2022年底可以看到失业率在3%左右，”Feroli称。“过去五个月的失业率下降幅度令人深刻印象。我们预计下降速度会放缓，但很快就会降至4%以下。”\n在Feroli看来，随着雇主寻找人才以推动企业从疫情中复苏，就业市场可能会以良好的势头进入2022年。\nFeroli还预计，明年美国GDP将增长3%。他认为，美联储将在9月开始加息以抵消通胀，而通胀在一定程度上是由于劳动力市场状况吃紧。\n此外，就业市场的一个主要风险仍然是奥密克戎变体及其是否会减缓企业的招聘计划。","news_type":1,"symbols_score_info":{"161125":0.9,"513500":0.9,"DOG":0.9,"ESmain":0.9,"DDM":0.9,"SQQQ":0.9,"QID":0.9,"MNQmain":0.9,".IXIC":0.9,"OEX":0.9,"SDS":0.9,".SPX":0.9,"TQQQ":0.9,".DJI":0.9,"QLD":0.9,"PSQ":0.9,"SPY":0.9,"NQmain":0.9,"OEF":0.9,"QQQ":0.9,"UPRO":0.9,"UDOW":0.9,"SDOW":0.9,"SSO":0.9,"DJX":0.9,"SPXU":0.9,"IVV":0.9,"SH":0.9,"DXD":0.9}},"isVote":1,"tweetType":1,"viewCount":2228,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600070576,"gmtCreate":1638023352649,"gmtModify":1638023352846,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Haiz","listText":"Haiz","text":"Haiz","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600070576","repostId":"2186344334","repostType":4,"isVote":1,"tweetType":1,"viewCount":2552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873952288,"gmtCreate":1636849821806,"gmtModify":1636849821984,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873952288","repostId":"1129004768","repostType":4,"repost":{"id":"1129004768","kind":"news","pubTimestamp":1636764434,"share":"https://www.laohu8.com/m/news/1129004768?lang=zh_CN&edition=full","pubTime":"2021-11-13 08:47","market":"us","language":"en","title":"Apple: The Bear Argument, And Why It's Wrong<blockquote>苹果：熊市论点及其错误的原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129004768","media":"Seeking Alpha","summary":"Apple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.I list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.Maybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.This may also help to explain, in part, why Apple's revenues in Greater China shot through the","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.</li>  <li>I list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.</li>  <li>Maybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4bc955cc5d27328c3b89b327b9368d27\" tg-width=\"1536\" tg-height=\"1020\" width=\"100%\" height=\"auto\"><span>kmwphotography/iStock via Getty Images</span></p><p><blockquote><ul><li>苹果未能长期保持在每股150美元以上，空头开始关注近期价格的疲软。</li><li>我列出了几个最流行的看跌论点，并解释了为什么我认为它们要么是短视的，要么很可能是不正确的。</li><li>也许苹果公司并不是同样值得买入的股票，但我仍然认为这是一只今天值得在未来几年持有的股票。</li></ul><p class=\"t-img-caption\"><span>kmwphotography/iStock来自Getty Images</span></p></blockquote></p><p> With Apple (AAPL) once again failing to make fresh all-time highs, now down around 6% from the peak and dipping closer towards key moving-average support, bears have started to pay attention. Still, I think that the case for selling (or shorting) this stock does not hold much water in the long term, and I believe that bears will ultimately tire of swimming against the current.</p><p><blockquote>随着苹果(AAPL)再次未能创下历史新高，目前较峰值下跌约6%，并接近关键移动平均线支撑位，空头开始关注。尽管如此，我认为从长远来看，出售（或做空）这只股票的理由并不成立，而且我相信空头最终会厌倦逆流而上。</blockquote></p><p> Below, I list the most common few reasons why one might want to dump or stay away from Apple shares – and why I think that the bearish case is either short-sighted or most likely incorrect.</p><p><blockquote>下面，我列出了人们可能想要抛售或远离苹果股票的几个最常见的原因，以及为什么我认为看跌情况要么是短视的，要么很可能是不正确的。</blockquote></p><p> <b>Key risk #1: drop-off in demand</b></p><p><blockquote><b>关键风险#1：需求下降</b></blockquote></p><p> Not many analysts and portfolio managers have been vocal about avoiding or selling Apple. Experts like New Street's&nbsp;Pierre Ferragu&nbsp;and Satori Fund's&nbsp;Dan Niles&nbsp;are the few that come to mind, and their theses seem to align pretty well with every other bearish call on AAPL that I have seen recently.</p><p><blockquote>没有多少分析师和投资组合经理公开表示要避免或出售苹果。像New Street的Pierre Ferragu和Satori Fund的Dan Niles这样的专家是我想到的少数几个，他们的论点似乎与我最近看到的所有其他看跌AAPL的看涨期权非常一致。</blockquote></p><p> The first common reason to sell the stock is often phrased in different ways, but can effectively be summarized as follows: Apple's financial results in the near term should suffer from demand that has already turned into revenues in calendar 2020, during the thick of the pandemic and stay-at-home consumption wave. This is particularly true following the launch of the iPhone 13 that some (including legendary Apple founder&nbsp;Steve Wozniak) see as merely a minor upgrade from the previous model.</p><p><blockquote>出售股票的第一个常见原因通常以不同的方式表述，但可以有效地总结如下：苹果近期的财务业绩应该会受到需求的影响，而需求已经在2020年疫情最严重的时候转化为收入和居家消费浪潮。在iPhone 13发布之后尤其如此，一些人（包括传奇的苹果创始人Steve Wozniak）认为iPhone 13只是对上一款机型的小幅升级。</blockquote></p><p> I see the concern here, especially considering that Apple will start to face unsurmountable iPhone comps in the holidays and post-holiday quarters – see graph below. But the same chart also shows that there seemed to exist quite a bit of pent-up demand over the many quarters that preceded the iPhone 12 launch. One possible justification for this shift in sales from fiscal 2019-2020 to 2021 is Apple's late entry into the 5G space. Consumers that are loyal to or just prefer the iOS device probably waited patiently to upgrade or switch, and then they did it all at once.</p><p><blockquote>我看到了这里的担忧，特别是考虑到苹果将在假期和节后季度开始面临无法克服的iPhone竞争——见下图。但同一张图表还显示，在iPhone 12发布之前的许多季度中，似乎存在相当多被压抑的需求。销售额从2019-2020财年转移到2021财年的一个可能原因是苹果进入5G领域较晚。忠于或只是喜欢iOS设备的消费者可能会耐心等待升级或切换，然后他们一下子就完成了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7dc677f0a1c77dd39f40b4cc99c6fc15\" tg-width=\"460\" tg-height=\"322\" width=\"100%\" height=\"auto\"><span>Source: DM Martins Research, data from company reports</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：DM Martins Research，数据来自公司报告</span></p></blockquote></p><p> This may also help to explain, in part, why Apple's revenues in Greater China shot through the roof in the past 6 to 12 months. With the country's 5G infrastructure being further developed, owning a device that can handle the faster speeds probably makes most sense. Sales in the region had been lackluster to say the least since 2015, and dropped YOY by as much as 29% in fiscal Q4 of 2020. In the past three quarters, however, revenues climbed by at least 57% in each period.</p><p><blockquote>这也可能有助于部分解释为什么苹果在大中华区的收入在过去6至12个月内飙升。随着该国5G基础设施的进一步发展，拥有一款能够处理更快速度的设备可能是最有意义的。至少可以说，自2015年以来，该地区的销售额一直低迷，2020财年第四季度同比下降了29%。然而，在过去三个季度中，每个季度的收入都至少增长了57%。</blockquote></p><p> In the end, over the last 12 quarters – i.e. roughly the useful life of the average iPhone – Apple's smartphone sales have risen by only 4.8% per year. Considering that ASP (average selling price) has likely increased during the period, this figure barely represents any meaningful growth in device shipments over a full cycle. Therefore, to think that demand for Apple's products will fall off a cliff next seems like a stretch, especially if one also considers chip innovation and design updates in Mac and iPad.</p><p><blockquote>最终，在过去的12个季度（大约是iPhone的平均使用寿命）中，苹果的智能手机销量每年仅增长4.8%。考虑到ASP（平均售价）在此期间可能有所上涨，这一数字几乎不能代表整个周期内设备出货量的任何有意义的增长。因此，认为接下来对苹果产品的需求会断崖式下跌似乎有些牵强，特别是如果还考虑到Mac和iPad的芯片创新和设计更新的话。</blockquote></p><p> <b>Key risk #2: valuation</b></p><p><blockquote><b>关键风险#2：估值</b></blockquote></p><p> The other key risk of investing in Apple that is often brought up is valuation. Dan Niles, mentioned above, suggests that a next-year P/E of 26 times might not even be the biggest deal. The problem is that this multiple looks too rich against growth expectations that are modest.Analysts expect Apple's EPS&nbsp;to rise by only 4% per year through fiscal 2025. Alphabet (GOOG)(GOOGL), valued at a similar earnings multiple, is expected to drive earnings 16% higher per year over a similar period.</p><p><blockquote>投资苹果经常被提及的另一个主要风险是估值。上面提到的丹·奈尔斯(Dan Niles)表示，明年26倍的市盈率可能甚至不是最大的交易。问题是，与温和的增长预期相比，这个市盈率看起来太高了。分析师预计，到2025财年，苹果的每股收益每年仅增长4%。Alphabet(GOOG)（GOOGL）的市盈率相似，预计同期盈利每年将增长16%。</blockquote></p><p> That, in my view, is a more reasonable bearish argument. Per my estimates, Apple is by far the stock with the highest PEG ratio (P/E over long-term EPS growth) of 6.5 times. Amazon (AMZN) is a very distant second on this metric, at 2.3 times. But even here, I see a good argument to be made in favor of Apple.</p><p><blockquote>在我看来，这是一个更合理的看跌论点。根据我的估计，苹果是迄今为止PEG比率（市盈率超过长期每股收益增长）最高的股票，为6.5倍。亚马逊(AMZN)在这一指标上远远落后于第二名，为2.3倍。但即使在这里，我也看到了一个支持苹果的好理由。</blockquote></p><p></p><p> First, the company has been proving to be a powerful gatekeeper in the tech world. Here is one example: the first, most blatant sign that Apple's iOS privacy policy changes in the summer&nbsp;have been hurting social media companies&nbsp;and their financial statements&nbsp;led to the Nasdaqe&nbsp;rasing $120 billion in market value in a matter of minutes – most of which coming from internet stocks. Should one be expected to pay a premium for a stock in the face of such market control? I would say so.</p><p><blockquote>首先，该公司已被证明是科技界强大的看门人。这里有一个例子：第一个也是最明显的迹象表明，苹果今年夏天iOS隐私政策的变化一直在损害社交媒体公司，它们的财务报表导致纳斯达克在几分钟内市值飙升1200亿美元——其中大部分来自互联网股票。面对这种市场控制，人们应该为股票支付溢价吗？我会这么说。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0946db3f3bc62569a56f2dbe2aa75922\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Also, as the chart above depicts, Apple's forward-year P/E has certainly expanded relative to what it used to be a few years ago. But the multi-year move higher seems consistent with (1) a wave of increased demand for Apple's products and services, (2) better margins, (3) a drop in interest rates in 2020, and (4) a broad stock market that has become generally more expensive. Compared to how AAPL traded only about three months ago, P/E has in fact dipped about three turns and returned to early 2021 levels.</p><p><blockquote>此外，如上图所示，苹果的远期市盈率相对于几年前肯定有所扩大。但多年来的上涨似乎与(1)对苹果产品和服务的需求增加浪潮、(2)利润率提高、(3)2020年利率下降以及(4)广泛的股市一致市场普遍变得更加昂贵。与大约三个月前AAPL的交易方式相比，市盈率实际上已经下降了大约三圈，并回到了2021年初的水平。</blockquote></p><p> <b>Key risk #3: lack of positive catalysts</b></p><p><blockquote><b>关键风险#3：缺乏积极的催化剂</b></blockquote></p><p> The next risk to investing in Apple that is often cited are short-term catalysts. The iPhone 13 was announced a few weeks ago, and&nbsp;so has the refreshed lineup&nbsp;of MacBook Pro devices equipped with the new M1 Pro and Max chips. Fiscal fourth quarter earnings is also in the rearview mirror. In fact, I think that the drop off in relevant Apple news in the fourth quarter correlates well with a stock that, seasonally, tends to perform worse in the November-to-January period. Bears may also argue that, with a few quarters of tough comps ahead, investors might have a hard time finding reasons to buy AAPL in the next few months.</p><p><blockquote>经常提到的投资苹果的下一个风险是短期催化剂。iPhone 13在几周前发布，配备新M1 Pro和Max芯片的MacBook Pro设备的更新阵容也是如此。第四财季盈利也已成为过去。事实上，我认为第四季度相关苹果新闻的下降与一只股票在11月至1月期间季节性表现往往较差的股票密切相关。看空者还可能辩称，由于未来几个季度的业绩艰难，投资者可能很难在未来几个月内找到购买苹果公司的理由。</blockquote></p><p> But here, I believe that a bit of patience is warranted. First, the recent malaise in share price alone may be enough to attract new money from investors looking for a good deal on a high-quality stock. But more importantly, longer-term catalysts are likely to make more of a difference on share price and financial performance over the next, say, five years.</p><p><blockquote>但在这里，我认为需要一点耐心。首先，仅最近股价的低迷就足以吸引寻求优质股票优惠的投资者的新资金。但更重要的是，长期催化剂可能会在未来五年内对股价和财务业绩产生更大影响。</blockquote></p><p> I have previously talked in more detail about two catalysts that quickly come to mind. I doubt that much upside from initiatives like mixed reality and&nbsp;autonomous vehicle&nbsp;has been factored into analysts' financial models – and hence, properly priced into the stock. Because Apple is run by a conservative team of executives, I bet that both massive growth opportunities will be pursued if and when they are accretive to the company's earnings. They should, therefore, serve as the key catalysts driving long-term growth expectations (which is relevant for risk #1 above) and share price higher.</p><p><blockquote>我之前已经更详细地谈到了两个很快浮现在脑海中的催化剂。我怀疑混合现实和自动驾驶汽车等举措的太大好处是否已纳入分析师的财务模型，因此也无法正确定价到股票中。由于苹果是由一个保守的高管团队运营的，我敢打赌，如果这两个巨大的增长机会能够增加公司的盈利，那么它们就会被追求。因此，它们应该成为推动长期增长预期（与上述风险#1相关）和股价上涨的关键催化剂。</blockquote></p><p> <b>In summary</b></p><p><blockquote><b>总之</b></blockquote></p><p> Apple may not be the same pound-the-table opportunity that I believed it to be&nbsp;in February 2021&nbsp;or, better yet,in April 2018&nbsp;– in both cases, I believed that shares had sold off for no good reason. But I continue to think that AAPL is a stock to own today through the next several years, especially now that the earnings multiple has started to rerate towards year-ago levels. Should Apple continue to head lower in the near term, the pullback (assuming no meaningful change in business fundamentals) would present an even better chance to buy.</p><p><blockquote>苹果可能不像我在2021年2月或更好的2018年4月那样是一个巨大的机会——在这两种情况下，我都认为股票毫无理由地遭到抛售。但我仍然认为，苹果公司是一只值得在未来几年持有的股票，尤其是现在市盈率已开始重估至去年同期的水平。如果苹果短期内继续走低，回调（假设商业基本面没有发生有意义的变化）将提供更好的买入机会。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple: The Bear Argument, And Why It's Wrong<blockquote>苹果：熊市论点及其错误的原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple: The Bear Argument, And Why It's Wrong<blockquote>苹果：熊市论点及其错误的原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-11-13 08:47</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Apple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.</li>  <li>I list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.</li>  <li>Maybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4bc955cc5d27328c3b89b327b9368d27\" tg-width=\"1536\" tg-height=\"1020\" width=\"100%\" height=\"auto\"><span>kmwphotography/iStock via Getty Images</span></p><p><blockquote><ul><li>苹果未能长期保持在每股150美元以上，空头开始关注近期价格的疲软。</li><li>我列出了几个最流行的看跌论点，并解释了为什么我认为它们要么是短视的，要么很可能是不正确的。</li><li>也许苹果公司并不是同样值得买入的股票，但我仍然认为这是一只今天值得在未来几年持有的股票。</li></ul><p class=\"t-img-caption\"><span>kmwphotography/iStock来自Getty Images</span></p></blockquote></p><p> With Apple (AAPL) once again failing to make fresh all-time highs, now down around 6% from the peak and dipping closer towards key moving-average support, bears have started to pay attention. Still, I think that the case for selling (or shorting) this stock does not hold much water in the long term, and I believe that bears will ultimately tire of swimming against the current.</p><p><blockquote>随着苹果(AAPL)再次未能创下历史新高，目前较峰值下跌约6%，并接近关键移动平均线支撑位，空头开始关注。尽管如此，我认为从长远来看，出售（或做空）这只股票的理由并不成立，而且我相信空头最终会厌倦逆流而上。</blockquote></p><p> Below, I list the most common few reasons why one might want to dump or stay away from Apple shares – and why I think that the bearish case is either short-sighted or most likely incorrect.</p><p><blockquote>下面，我列出了人们可能想要抛售或远离苹果股票的几个最常见的原因，以及为什么我认为看跌情况要么是短视的，要么很可能是不正确的。</blockquote></p><p> <b>Key risk #1: drop-off in demand</b></p><p><blockquote><b>关键风险#1：需求下降</b></blockquote></p><p> Not many analysts and portfolio managers have been vocal about avoiding or selling Apple. Experts like New Street's&nbsp;Pierre Ferragu&nbsp;and Satori Fund's&nbsp;Dan Niles&nbsp;are the few that come to mind, and their theses seem to align pretty well with every other bearish call on AAPL that I have seen recently.</p><p><blockquote>没有多少分析师和投资组合经理公开表示要避免或出售苹果。像New Street的Pierre Ferragu和Satori Fund的Dan Niles这样的专家是我想到的少数几个，他们的论点似乎与我最近看到的所有其他看跌AAPL的看涨期权非常一致。</blockquote></p><p> The first common reason to sell the stock is often phrased in different ways, but can effectively be summarized as follows: Apple's financial results in the near term should suffer from demand that has already turned into revenues in calendar 2020, during the thick of the pandemic and stay-at-home consumption wave. This is particularly true following the launch of the iPhone 13 that some (including legendary Apple founder&nbsp;Steve Wozniak) see as merely a minor upgrade from the previous model.</p><p><blockquote>出售股票的第一个常见原因通常以不同的方式表述，但可以有效地总结如下：苹果近期的财务业绩应该会受到需求的影响，而需求已经在2020年疫情最严重的时候转化为收入和居家消费浪潮。在iPhone 13发布之后尤其如此，一些人（包括传奇的苹果创始人Steve Wozniak）认为iPhone 13只是对上一款机型的小幅升级。</blockquote></p><p> I see the concern here, especially considering that Apple will start to face unsurmountable iPhone comps in the holidays and post-holiday quarters – see graph below. But the same chart also shows that there seemed to exist quite a bit of pent-up demand over the many quarters that preceded the iPhone 12 launch. One possible justification for this shift in sales from fiscal 2019-2020 to 2021 is Apple's late entry into the 5G space. Consumers that are loyal to or just prefer the iOS device probably waited patiently to upgrade or switch, and then they did it all at once.</p><p><blockquote>我看到了这里的担忧，特别是考虑到苹果将在假期和节后季度开始面临无法克服的iPhone竞争——见下图。但同一张图表还显示，在iPhone 12发布之前的许多季度中，似乎存在相当多被压抑的需求。销售额从2019-2020财年转移到2021财年的一个可能原因是苹果进入5G领域较晚。忠于或只是喜欢iOS设备的消费者可能会耐心等待升级或切换，然后他们一下子就完成了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7dc677f0a1c77dd39f40b4cc99c6fc15\" tg-width=\"460\" tg-height=\"322\" width=\"100%\" height=\"auto\"><span>Source: DM Martins Research, data from company reports</span></p><p><blockquote><p class=\"t-img-caption\"><span>资料来源：DM Martins Research，数据来自公司报告</span></p></blockquote></p><p> This may also help to explain, in part, why Apple's revenues in Greater China shot through the roof in the past 6 to 12 months. With the country's 5G infrastructure being further developed, owning a device that can handle the faster speeds probably makes most sense. Sales in the region had been lackluster to say the least since 2015, and dropped YOY by as much as 29% in fiscal Q4 of 2020. In the past three quarters, however, revenues climbed by at least 57% in each period.</p><p><blockquote>这也可能有助于部分解释为什么苹果在大中华区的收入在过去6至12个月内飙升。随着该国5G基础设施的进一步发展，拥有一款能够处理更快速度的设备可能是最有意义的。至少可以说，自2015年以来，该地区的销售额一直低迷，2020财年第四季度同比下降了29%。然而，在过去三个季度中，每个季度的收入都至少增长了57%。</blockquote></p><p> In the end, over the last 12 quarters – i.e. roughly the useful life of the average iPhone – Apple's smartphone sales have risen by only 4.8% per year. Considering that ASP (average selling price) has likely increased during the period, this figure barely represents any meaningful growth in device shipments over a full cycle. Therefore, to think that demand for Apple's products will fall off a cliff next seems like a stretch, especially if one also considers chip innovation and design updates in Mac and iPad.</p><p><blockquote>最终，在过去的12个季度（大约是iPhone的平均使用寿命）中，苹果的智能手机销量每年仅增长4.8%。考虑到ASP（平均售价）在此期间可能有所上涨，这一数字几乎不能代表整个周期内设备出货量的任何有意义的增长。因此，认为接下来对苹果产品的需求会断崖式下跌似乎有些牵强，特别是如果还考虑到Mac和iPad的芯片创新和设计更新的话。</blockquote></p><p> <b>Key risk #2: valuation</b></p><p><blockquote><b>关键风险#2：估值</b></blockquote></p><p> The other key risk of investing in Apple that is often brought up is valuation. Dan Niles, mentioned above, suggests that a next-year P/E of 26 times might not even be the biggest deal. The problem is that this multiple looks too rich against growth expectations that are modest.Analysts expect Apple's EPS&nbsp;to rise by only 4% per year through fiscal 2025. Alphabet (GOOG)(GOOGL), valued at a similar earnings multiple, is expected to drive earnings 16% higher per year over a similar period.</p><p><blockquote>投资苹果经常被提及的另一个主要风险是估值。上面提到的丹·奈尔斯(Dan Niles)表示，明年26倍的市盈率可能甚至不是最大的交易。问题是，与温和的增长预期相比，这个市盈率看起来太高了。分析师预计，到2025财年，苹果的每股收益每年仅增长4%。Alphabet(GOOG)（GOOGL）的市盈率相似，预计同期盈利每年将增长16%。</blockquote></p><p> That, in my view, is a more reasonable bearish argument. Per my estimates, Apple is by far the stock with the highest PEG ratio (P/E over long-term EPS growth) of 6.5 times. Amazon (AMZN) is a very distant second on this metric, at 2.3 times. But even here, I see a good argument to be made in favor of Apple.</p><p><blockquote>在我看来，这是一个更合理的看跌论点。根据我的估计，苹果是迄今为止PEG比率（市盈率超过长期每股收益增长）最高的股票，为6.5倍。亚马逊(AMZN)在这一指标上远远落后于第二名，为2.3倍。但即使在这里，我也看到了一个支持苹果的好理由。</blockquote></p><p></p><p> First, the company has been proving to be a powerful gatekeeper in the tech world. Here is one example: the first, most blatant sign that Apple's iOS privacy policy changes in the summer&nbsp;have been hurting social media companies&nbsp;and their financial statements&nbsp;led to the Nasdaqe&nbsp;rasing $120 billion in market value in a matter of minutes – most of which coming from internet stocks. Should one be expected to pay a premium for a stock in the face of such market control? I would say so.</p><p><blockquote>首先，该公司已被证明是科技界强大的看门人。这里有一个例子：第一个也是最明显的迹象表明，苹果今年夏天iOS隐私政策的变化一直在损害社交媒体公司，它们的财务报表导致纳斯达克在几分钟内市值飙升1200亿美元——其中大部分来自互联网股票。面对这种市场控制，人们应该为股票支付溢价吗？我会这么说。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0946db3f3bc62569a56f2dbe2aa75922\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据来自YCharts</span></p></blockquote></p><p> Also, as the chart above depicts, Apple's forward-year P/E has certainly expanded relative to what it used to be a few years ago. But the multi-year move higher seems consistent with (1) a wave of increased demand for Apple's products and services, (2) better margins, (3) a drop in interest rates in 2020, and (4) a broad stock market that has become generally more expensive. Compared to how AAPL traded only about three months ago, P/E has in fact dipped about three turns and returned to early 2021 levels.</p><p><blockquote>此外，如上图所示，苹果的远期市盈率相对于几年前肯定有所扩大。但多年来的上涨似乎与(1)对苹果产品和服务的需求增加浪潮、(2)利润率提高、(3)2020年利率下降以及(4)广泛的股市一致市场普遍变得更加昂贵。与大约三个月前AAPL的交易方式相比，市盈率实际上已经下降了大约三圈，并回到了2021年初的水平。</blockquote></p><p> <b>Key risk #3: lack of positive catalysts</b></p><p><blockquote><b>关键风险#3：缺乏积极的催化剂</b></blockquote></p><p> The next risk to investing in Apple that is often cited are short-term catalysts. The iPhone 13 was announced a few weeks ago, and&nbsp;so has the refreshed lineup&nbsp;of MacBook Pro devices equipped with the new M1 Pro and Max chips. Fiscal fourth quarter earnings is also in the rearview mirror. In fact, I think that the drop off in relevant Apple news in the fourth quarter correlates well with a stock that, seasonally, tends to perform worse in the November-to-January period. Bears may also argue that, with a few quarters of tough comps ahead, investors might have a hard time finding reasons to buy AAPL in the next few months.</p><p><blockquote>经常提到的投资苹果的下一个风险是短期催化剂。iPhone 13在几周前发布，配备新M1 Pro和Max芯片的MacBook Pro设备的更新阵容也是如此。第四财季盈利也已成为过去。事实上，我认为第四季度相关苹果新闻的下降与一只股票在11月至1月期间季节性表现往往较差的股票密切相关。看空者还可能辩称，由于未来几个季度的业绩艰难，投资者可能很难在未来几个月内找到购买苹果公司的理由。</blockquote></p><p> But here, I believe that a bit of patience is warranted. First, the recent malaise in share price alone may be enough to attract new money from investors looking for a good deal on a high-quality stock. But more importantly, longer-term catalysts are likely to make more of a difference on share price and financial performance over the next, say, five years.</p><p><blockquote>但在这里，我认为需要一点耐心。首先，仅最近股价的低迷就足以吸引寻求优质股票优惠的投资者的新资金。但更重要的是，长期催化剂可能会在未来五年内对股价和财务业绩产生更大影响。</blockquote></p><p> I have previously talked in more detail about two catalysts that quickly come to mind. I doubt that much upside from initiatives like mixed reality and&nbsp;autonomous vehicle&nbsp;has been factored into analysts' financial models – and hence, properly priced into the stock. Because Apple is run by a conservative team of executives, I bet that both massive growth opportunities will be pursued if and when they are accretive to the company's earnings. They should, therefore, serve as the key catalysts driving long-term growth expectations (which is relevant for risk #1 above) and share price higher.</p><p><blockquote>我之前已经更详细地谈到了两个很快浮现在脑海中的催化剂。我怀疑混合现实和自动驾驶汽车等举措的太大好处是否已纳入分析师的财务模型，因此也无法正确定价到股票中。由于苹果是由一个保守的高管团队运营的，我敢打赌，如果这两个巨大的增长机会能够增加公司的盈利，那么它们就会被追求。因此，它们应该成为推动长期增长预期（与上述风险#1相关）和股价上涨的关键催化剂。</blockquote></p><p> <b>In summary</b></p><p><blockquote><b>总之</b></blockquote></p><p> Apple may not be the same pound-the-table opportunity that I believed it to be&nbsp;in February 2021&nbsp;or, better yet,in April 2018&nbsp;– in both cases, I believed that shares had sold off for no good reason. But I continue to think that AAPL is a stock to own today through the next several years, especially now that the earnings multiple has started to rerate towards year-ago levels. Should Apple continue to head lower in the near term, the pullback (assuming no meaningful change in business fundamentals) would present an even better chance to buy.</p><p><blockquote>苹果可能不像我在2021年2月或更好的2018年4月那样是一个巨大的机会——在这两种情况下，我都认为股票毫无理由地遭到抛售。但我仍然认为，苹果公司是一只值得在未来几年持有的股票，尤其是现在市盈率已开始重估至去年同期的水平。如果苹果短期内继续走低，回调（假设商业基本面没有发生有意义的变化）将提供更好的买入机会。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4468890-apple-the-bear-argument-and-why-its-wrong\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://seekingalpha.com/article/4468890-apple-the-bear-argument-and-why-its-wrong","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129004768","content_text":"Summary\n\nApple has failed to stay above $150 per share for long, and bears are starting to pay attention to the recent weakness in price.\nI list a couple of the most popular bearish arguments, and explain why I believe that they are either short-sighted or most likely incorrect.\nMaybe AAPL is not the same pound-the-table buy, but I continue to think that this is a stock to own today through the next several years.\n\nkmwphotography/iStock via Getty Images\nWith Apple (AAPL) once again failing to make fresh all-time highs, now down around 6% from the peak and dipping closer towards key moving-average support, bears have started to pay attention. Still, I think that the case for selling (or shorting) this stock does not hold much water in the long term, and I believe that bears will ultimately tire of swimming against the current.\nBelow, I list the most common few reasons why one might want to dump or stay away from Apple shares – and why I think that the bearish case is either short-sighted or most likely incorrect.\nKey risk #1: drop-off in demand\nNot many analysts and portfolio managers have been vocal about avoiding or selling Apple. Experts like New Street's Pierre Ferragu and Satori Fund's Dan Niles are the few that come to mind, and their theses seem to align pretty well with every other bearish call on AAPL that I have seen recently.\nThe first common reason to sell the stock is often phrased in different ways, but can effectively be summarized as follows: Apple's financial results in the near term should suffer from demand that has already turned into revenues in calendar 2020, during the thick of the pandemic and stay-at-home consumption wave. This is particularly true following the launch of the iPhone 13 that some (including legendary Apple founder Steve Wozniak) see as merely a minor upgrade from the previous model.\nI see the concern here, especially considering that Apple will start to face unsurmountable iPhone comps in the holidays and post-holiday quarters – see graph below. But the same chart also shows that there seemed to exist quite a bit of pent-up demand over the many quarters that preceded the iPhone 12 launch. One possible justification for this shift in sales from fiscal 2019-2020 to 2021 is Apple's late entry into the 5G space. Consumers that are loyal to or just prefer the iOS device probably waited patiently to upgrade or switch, and then they did it all at once.\nSource: DM Martins Research, data from company reports\nThis may also help to explain, in part, why Apple's revenues in Greater China shot through the roof in the past 6 to 12 months. With the country's 5G infrastructure being further developed, owning a device that can handle the faster speeds probably makes most sense. Sales in the region had been lackluster to say the least since 2015, and dropped YOY by as much as 29% in fiscal Q4 of 2020. In the past three quarters, however, revenues climbed by at least 57% in each period.\nIn the end, over the last 12 quarters – i.e. roughly the useful life of the average iPhone – Apple's smartphone sales have risen by only 4.8% per year. Considering that ASP (average selling price) has likely increased during the period, this figure barely represents any meaningful growth in device shipments over a full cycle. Therefore, to think that demand for Apple's products will fall off a cliff next seems like a stretch, especially if one also considers chip innovation and design updates in Mac and iPad.\nKey risk #2: valuation\nThe other key risk of investing in Apple that is often brought up is valuation. Dan Niles, mentioned above, suggests that a next-year P/E of 26 times might not even be the biggest deal. The problem is that this multiple looks too rich against growth expectations that are modest.Analysts expect Apple's EPS to rise by only 4% per year through fiscal 2025. Alphabet (GOOG)(GOOGL), valued at a similar earnings multiple, is expected to drive earnings 16% higher per year over a similar period.\nThat, in my view, is a more reasonable bearish argument. Per my estimates, Apple is by far the stock with the highest PEG ratio (P/E over long-term EPS growth) of 6.5 times. Amazon (AMZN) is a very distant second on this metric, at 2.3 times. But even here, I see a good argument to be made in favor of Apple.\nFirst, the company has been proving to be a powerful gatekeeper in the tech world. Here is one example: the first, most blatant sign that Apple's iOS privacy policy changes in the summer have been hurting social media companies and their financial statements led to the Nasdaqe rasing $120 billion in market value in a matter of minutes – most of which coming from internet stocks. Should one be expected to pay a premium for a stock in the face of such market control? I would say so.\nData by YCharts\nAlso, as the chart above depicts, Apple's forward-year P/E has certainly expanded relative to what it used to be a few years ago. But the multi-year move higher seems consistent with (1) a wave of increased demand for Apple's products and services, (2) better margins, (3) a drop in interest rates in 2020, and (4) a broad stock market that has become generally more expensive. Compared to how AAPL traded only about three months ago, P/E has in fact dipped about three turns and returned to early 2021 levels.\nKey risk #3: lack of positive catalysts\nThe next risk to investing in Apple that is often cited are short-term catalysts. The iPhone 13 was announced a few weeks ago, and so has the refreshed lineup of MacBook Pro devices equipped with the new M1 Pro and Max chips. Fiscal fourth quarter earnings is also in the rearview mirror. In fact, I think that the drop off in relevant Apple news in the fourth quarter correlates well with a stock that, seasonally, tends to perform worse in the November-to-January period. Bears may also argue that, with a few quarters of tough comps ahead, investors might have a hard time finding reasons to buy AAPL in the next few months.\nBut here, I believe that a bit of patience is warranted. First, the recent malaise in share price alone may be enough to attract new money from investors looking for a good deal on a high-quality stock. But more importantly, longer-term catalysts are likely to make more of a difference on share price and financial performance over the next, say, five years.\nI have previously talked in more detail about two catalysts that quickly come to mind. I doubt that much upside from initiatives like mixed reality and autonomous vehicle has been factored into analysts' financial models – and hence, properly priced into the stock. Because Apple is run by a conservative team of executives, I bet that both massive growth opportunities will be pursued if and when they are accretive to the company's earnings. They should, therefore, serve as the key catalysts driving long-term growth expectations (which is relevant for risk #1 above) and share price higher.\nIn summary\nApple may not be the same pound-the-table opportunity that I believed it to be in February 2021 or, better yet,in April 2018 – in both cases, I believed that shares had sold off for no good reason. But I continue to think that AAPL is a stock to own today through the next several years, especially now that the earnings multiple has started to rerate towards year-ago levels. Should Apple continue to head lower in the near term, the pullback (assuming no meaningful change in business fundamentals) would present an even better chance to buy.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872622320,"gmtCreate":1637509764766,"gmtModify":1637509764996,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872622320","repostId":"1136453612","repostType":4,"repost":{"id":"1136453612","kind":"news","pubTimestamp":1637458211,"share":"https://www.laohu8.com/m/news/1136453612?lang=zh_CN&edition=full","pubTime":"2021-11-21 09:30","market":"us","language":"en","title":"UBS Picks Former Morgan Stanley President Kelleher As chairman, Deutsche Bank Nominates Alexander Wynaendts As Next Chairman<blockquote>瑞银选择摩根士丹利前总裁凯莱赫为董事长，德意志银行提名亚历山大·怀南茨为下一任董事长</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136453612","media":"Benzinga ","summary":"UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman.\nA day before,","content":"<p><div> UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman. A day before,Deutsche Bank announced that it would nominate Dutch businessman Alexander Wynaendts as the next ...</p><p><blockquote><div>瑞银集团任命摩根士丹利前总裁科尔姆·凯莱赫为新任董事长。一天前，德意志银行宣布提名荷兰商人亚历山大·怀南茨为下一任...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Picks Former Morgan Stanley President Kelleher As chairman, Deutsche Bank Nominates Alexander Wynaendts As Next Chairman<blockquote>瑞银选择摩根士丹利前总裁凯莱赫为董事长，德意志银行提名亚历山大·怀南茨为下一任董事长</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Picks Former Morgan Stanley President Kelleher As chairman, Deutsche Bank Nominates Alexander Wynaendts As Next Chairman<blockquote>瑞银选择摩根士丹利前总裁凯莱赫为董事长，德意志银行提名亚历山大·怀南茨为下一任董事长</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga </strong><span class=\"h-time small\">2021-11-21 09:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman. A day before,Deutsche Bank announced that it would nominate Dutch businessman Alexander Wynaendts as the next ...</p><p><blockquote><div>瑞银集团任命摩根士丹利前总裁科尔姆·凯莱赫为新任董事长。一天前，德意志银行宣布提名荷兰商人亚历山大·怀南茨为下一任...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn\">Benzinga </a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBS":"瑞银"},"source_url":"https://www.benzinga.com/news/21/11/24210567/ubs-picks-former-morgan-stanley-president-kelleher-as-chairman-deutsche-bank-nominates-alexander-wyn","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136453612","content_text":"UBS Group has named former Morgan Stanley President Colm Kelleher as its new chairman.\nA day before,Deutsche Bank announced that it would nominate Dutch businessman Alexander Wynaendts as the next chairman of its supervisory board, following a turbulent decade for Germany’s largest lender.\nKelleher will succeed Axel Weber as UBS’s chairman next year. He takes the leadership role having spent three decades at Morgan Stanley, where he served as chief financial officer before rising to the position of president.\nAccording to Reuters, UBS’s board had included former UniCredit Chief Executive Jean-Pierre Mustier in a shortlist of possible candidates.\nIn October, UBS posted its highest quarterly profit over the past 11 years, with a 23% rise in fee income.\nSimilarly, Wynaendts will replace Paul Achleitner at Deutsche Bank. The bank's shares have fallen more than 50% since Achleitner became chairman, primarily due to massive regulatory fines and repeated capital raisings.\nWynaendts ran Dutch insurer Aegon NV for 12 years before leaving in 2020, and previously worked at ABN Amro’s investment banking and private banking units before joining Aegon in 1997.","news_type":1,"symbols_score_info":{"UBS":0.9}},"isVote":1,"tweetType":1,"viewCount":2722,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604800763,"gmtCreate":1639364649863,"gmtModify":1639364924275,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604800763","repostId":"605462650","repostType":1,"repost":{"id":605462650,"gmtCreate":1639222201797,"gmtModify":1639233253732,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569316529855154","authorIdStr":"3569316529855154"},"themes":[],"title":"Sea Limited drops to end week","htmlText":"Sea Limited drops to end week as Hedgeye calls it a top short idea Back view of young gamer playing video games on computerSea Limited (NYSE:SE) ended the week on a low note, dropping 6.6% today after being named as a best idea short at Hedgeye.Shares had pulled back some 30% from their all-time highs already, analyst Felix Wang notes, but says the valuation is still \"lofty\" - and has room for another 35% downside.The company is facing more competitive pressure, he says, and some of the routes forward aren't as solid as expected. Sea is looking to Brazil to support international growth, but Wang says the gaming opportunity in Brazil is \"hyped\" and e-commerce there is shaky as well.As for its flagship game Garena Free Fire, it's a \"one-hit wonder whose performance has peaked,\" with engageme","listText":"Sea Limited drops to end week as Hedgeye calls it a top short idea Back view of young gamer playing video games on computerSea Limited (NYSE:SE) ended the week on a low note, dropping 6.6% today after being named as a best idea short at Hedgeye.Shares had pulled back some 30% from their all-time highs already, analyst Felix Wang notes, but says the valuation is still \"lofty\" - and has room for another 35% downside.The company is facing more competitive pressure, he says, and some of the routes forward aren't as solid as expected. Sea is looking to Brazil to support international growth, but Wang says the gaming opportunity in Brazil is \"hyped\" and e-commerce there is shaky as well.As for its flagship game Garena Free Fire, it's a \"one-hit wonder whose performance has peaked,\" with engageme","text":"Sea Limited drops to end week as Hedgeye calls it a top short idea Back view of young gamer playing video games on computerSea Limited (NYSE:SE) ended the week on a low note, dropping 6.6% today after being named as a best idea short at Hedgeye.Shares had pulled back some 30% from their all-time highs already, analyst Felix Wang notes, but says the valuation is still \"lofty\" - and has room for another 35% downside.The company is facing more competitive pressure, he says, and some of the routes forward aren't as solid as expected. Sea is looking to Brazil to support international growth, but Wang says the gaming opportunity in Brazil is \"hyped\" and e-commerce there is shaky as well.As for its flagship game Garena Free Fire, it's a \"one-hit wonder whose performance has peaked,\" with engageme","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605462650","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604800494,"gmtCreate":1639364635421,"gmtModify":1639364923690,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604800494","repostId":"605477626","repostType":1,"repost":{"id":605477626,"gmtCreate":1639236121452,"gmtModify":1747987191807,"author":{"id":"3548388348794551","authorId":"3548388348794551","name":"问就是加仓up","avatar":"https://static.tigerbbs.com/4e98ddf789d46c5627f944fc581c0fe9","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548388348794551","authorIdStr":"3548388348794551"},"themes":[],"title":"2021年复盘：大赚到接近清零，回本绝对是最浪漫的事","htmlText":"又到了年底复盘的时候，今年炒股体验真的极度复杂，年初觉得自己是股神， 年中觉得自己是韭菜，年底两个月又觉得自己能行了。这一年心路历程不是一篇帖子能够描述的，但还是希望通过年度复盘给大家还原一些比较有意义的观点。 这是去年的复盘链接&nbsp;&nbsp;<a href=\"https://laohu8.com/TW/331834662\" target=\"_blank\">2020总结：美股10倍，港股2倍，A股：赚钱是甚么</a> 今年的复盘主要分5个部分，收益复盘，操作复盘，一些感悟，交易手法，未来展望。文章有点长，可以直接跳转看自己感兴趣的部分。 1，收益：勉强保本 今年账户保本小赚，年中的时候一度大亏，在10月份开始飞速回本了，之后一路操作很多，但是也没啥大的收益。至于说收益图基本上也没法看，因为今年出入金频率太高，曲线都是-99%，因为中途出现过账户暴跌。但是由于控制了账户资金，没有受伤很严重。 这个图是12月10日截图，截止到今天一共交易了470w美金，交易频率比较高。累计交易了205只，其中盈利的只有43只，基本上就是赚钱的拿得住，赔钱的跑得快，当然也因此卖飞了不少股票。截止到今天一共挣了1600刀，收益率多少，我也不知道，根本算不出来。 另外今年开了N多的账户打新（几十个），这也是资金进出频繁的一个原因，不过这些账户都是亏钱出局，4月份之后基本上不打新了，打新是今年的一个重要亏损点。如果把所有账户加起来，今年基本上没赚钱，因为还有一个大账户也小有盈利，差不多可以把各种打野的亏损平衡掉。 2，操作复盘 每个月都有一些神之操作，每个月都有不一样的槽点。文中的时间节点可能记得不是那么清晰，相关操作之前发帖子也有提过，主要说一些印象比较深刻的。 1月份 中概股暴涨完整的吃到了，而且这也是账户高频交易的开始，当时买老虎股票，从6美金涨到了38美金（环球账户被清空了，没法晒）","listText":"又到了年底复盘的时候，今年炒股体验真的极度复杂，年初觉得自己是股神， 年中觉得自己是韭菜，年底两个月又觉得自己能行了。这一年心路历程不是一篇帖子能够描述的，但还是希望通过年度复盘给大家还原一些比较有意义的观点。 这是去年的复盘链接&nbsp;&nbsp;<a href=\"https://laohu8.com/TW/331834662\" target=\"_blank\">2020总结：美股10倍，港股2倍，A股：赚钱是甚么</a> 今年的复盘主要分5个部分，收益复盘，操作复盘，一些感悟，交易手法，未来展望。文章有点长，可以直接跳转看自己感兴趣的部分。 1，收益：勉强保本 今年账户保本小赚，年中的时候一度大亏，在10月份开始飞速回本了，之后一路操作很多，但是也没啥大的收益。至于说收益图基本上也没法看，因为今年出入金频率太高，曲线都是-99%，因为中途出现过账户暴跌。但是由于控制了账户资金，没有受伤很严重。 这个图是12月10日截图，截止到今天一共交易了470w美金，交易频率比较高。累计交易了205只，其中盈利的只有43只，基本上就是赚钱的拿得住，赔钱的跑得快，当然也因此卖飞了不少股票。截止到今天一共挣了1600刀，收益率多少，我也不知道，根本算不出来。 另外今年开了N多的账户打新（几十个），这也是资金进出频繁的一个原因，不过这些账户都是亏钱出局，4月份之后基本上不打新了，打新是今年的一个重要亏损点。如果把所有账户加起来，今年基本上没赚钱，因为还有一个大账户也小有盈利，差不多可以把各种打野的亏损平衡掉。 2，操作复盘 每个月都有一些神之操作，每个月都有不一样的槽点。文中的时间节点可能记得不是那么清晰，相关操作之前发帖子也有提过，主要说一些印象比较深刻的。 1月份 中概股暴涨完整的吃到了，而且这也是账户高频交易的开始，当时买老虎股票，从6美金涨到了38美金（环球账户被清空了，没法晒）","text":"又到了年底复盘的时候，今年炒股体验真的极度复杂，年初觉得自己是股神， 年中觉得自己是韭菜，年底两个月又觉得自己能行了。这一年心路历程不是一篇帖子能够描述的，但还是希望通过年度复盘给大家还原一些比较有意义的观点。 这是去年的复盘链接 2020总结：美股10倍，港股2倍，A股：赚钱是甚么 今年的复盘主要分5个部分，收益复盘，操作复盘，一些感悟，交易手法，未来展望。文章有点长，可以直接跳转看自己感兴趣的部分。 1，收益：勉强保本 今年账户保本小赚，年中的时候一度大亏，在10月份开始飞速回本了，之后一路操作很多，但是也没啥大的收益。至于说收益图基本上也没法看，因为今年出入金频率太高，曲线都是-99%，因为中途出现过账户暴跌。但是由于控制了账户资金，没有受伤很严重。 这个图是12月10日截图，截止到今天一共交易了470w美金，交易频率比较高。累计交易了205只，其中盈利的只有43只，基本上就是赚钱的拿得住，赔钱的跑得快，当然也因此卖飞了不少股票。截止到今天一共挣了1600刀，收益率多少，我也不知道，根本算不出来。 另外今年开了N多的账户打新（几十个），这也是资金进出频繁的一个原因，不过这些账户都是亏钱出局，4月份之后基本上不打新了，打新是今年的一个重要亏损点。如果把所有账户加起来，今年基本上没赚钱，因为还有一个大账户也小有盈利，差不多可以把各种打野的亏损平衡掉。 2，操作复盘 每个月都有一些神之操作，每个月都有不一样的槽点。文中的时间节点可能记得不是那么清晰，相关操作之前发帖子也有提过，主要说一些印象比较深刻的。 1月份 中概股暴涨完整的吃到了，而且这也是账户高频交易的开始，当时买老虎股票，从6美金涨到了38美金（环球账户被清空了，没法晒）","images":[{"img":"https://static.tigerbbs.com/fad4be5c0b8c595847d68aaeb0d403c7","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/b997c7eb8dab40ed1a413c3502e16b53","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/ccf5b3b2ff1b8703b1e8a4f1dfac346c","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605477626","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":1,"comments":[],"imageCount":16,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600079187,"gmtCreate":1638023420408,"gmtModify":1638023420654,"author":{"id":"3573948076022422","authorId":"3573948076022422","name":"Annie12345","avatar":"https://static.tigerbbs.com/b7529e308acffa5522a9e9690d9dcae6","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573948076022422","authorIdStr":"3573948076022422"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600079187","repostId":"875206593","repostType":1,"repost":{"id":875206593,"gmtCreate":1637653011508,"gmtModify":1637923972899,"author":{"id":"3585780691540522","authorId":"3585780691540522","name":"FundMall","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585780691540522","authorIdStr":"3585780691540522"},"themes":[],"title":"Fund College: When should you take profit?","htmlText":"One pertinent question investors commonly ask themselves is: ‘when should I take profits?’. This is no doubt a tough question to answer since we as investors are always seeking higher returns from our investments. In today’s article, we will break down our thoughts on this topic for our platform’s investors. To begin with, there is nothing wrong with chasing more returns despite having your investments in the green. However, we think that it is a good practice to review your portfolio at the end of the year or even the start of the year, even if you have a time horizon of ten years or more, given that sometimes a certain investment may become a huge part in your portfolio, especially if it has rallied aggressively. Take for example you have invested in the technology sector during the Covi","listText":"One pertinent question investors commonly ask themselves is: ‘when should I take profits?’. This is no doubt a tough question to answer since we as investors are always seeking higher returns from our investments. In today’s article, we will break down our thoughts on this topic for our platform’s investors. To begin with, there is nothing wrong with chasing more returns despite having your investments in the green. However, we think that it is a good practice to review your portfolio at the end of the year or even the start of the year, even if you have a time horizon of ten years or more, given that sometimes a certain investment may become a huge part in your portfolio, especially if it has rallied aggressively. Take for example you have invested in the technology sector during the Covi","text":"One pertinent question investors commonly ask themselves is: ‘when should I take profits?’. This is no doubt a tough question to answer since we as investors are always seeking higher returns from our investments. In today’s article, we will break down our thoughts on this topic for our platform’s investors. To begin with, there is nothing wrong with chasing more returns despite having your investments in the green. However, we think that it is a good practice to review your portfolio at the end of the year or even the start of the year, even if you have a time horizon of ten years or more, given that sometimes a certain investment may become a huge part in your portfolio, especially if it has rallied aggressively. Take for example you have invested in the technology sector during the Covi","images":[],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875206593","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}